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1) Overview of the Company1 
 
 
 
Bioserve clinical Research Private Limited is a USFDA certified Contract Research 
Organization promoted by professionals having over 30 years of experience in the 
Healthcare and Pharmaceutical industry. It offers a broad range of Clinical Services in 
compliance with applicable regulatory and ethical guidelines.  
Bioserve currently has a 92 Bedded GCP compliant clinical facility (Two independent 
clinics), capable of undertaking a variety of clinical studies.  
Bioserve clinical Research consists of four departments 
 
 Clinical  
 Bioanalytical  
 Pharmacokinetics and Statistics 
 Quality Assurance 
 
Clinical Unit is a 92 Bedded GCP compliant clinical facility (Three independent clinics), 
capable of undertaking a variety of clinical studies. The Clinical Units are Access 
Controlled with central monitoring with CCTV attached with well equipped Emergency 
room and a super specialty hospital, In-house dining and recreation for study participants. 
Separate areas for Sample Collection, Separation and sample Storage with -40/-80°C 
deep freezers. Facility to handle light sensitive and other products requiring special 
handling. In house canteen with dietician to plan and provide study specific diet to the 
subjects. 
 
Bioanalytical Unit is fully equipped lab offering HPLC and LCMS-MS analysis with 
Qualified and experienced team with over 40 years of experience. Access controlled 
secure sample storage/archival area with -40/-80 0C deep freezers with Eurotherm 5180V 
data logger for temperature monitoring. Dedicated sample processing area with all 
accessories including Positive pressure Solid Phase Extraction (SPE). Our Team is 
committed to science and meeting the challenges of research by providing seamless 
outsourcing solutions with professionalism, flexibility and reliability. Our strict 
compliance to regulatory requirements and our dedication to high quality, accurate results 
and a commitment to meet sponsor timelines are uncompromising. 
 
Bioserve is also an ISO 9001: 2000 certified facility approved by the Drugs Controller 
General of India and US-FDA Inspected 
 
Pharmacokinetics and Statistics team is crucial in coordinating clinical trials and a 
total involvement from design to analysis. The PK group also independently manages and 
access and temperature controlled pharmacy for the receipt, handling & archival of study 
drug products in accordance with the regulatory requirements. 
 
Quality Assurance provides expertise to ensure the conduct of client’s studies with the 
highest standards and also conducts independent audits to evaluate compliance with 
stipulations of all Standard Operating Procedures and applicable regulatory requirements. 
QA audits all clinical documents and complete source verification of information. Audits 
are conducted at regular intervals in order to enable early intervention and necessary 
corrective action.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 INTRODUCTION 
 
2.1 General Introduction2 
 
Bioavailability can be defined as the degree to which a substance is absorbed or becomes 
available at the site of physiological activity. It can also be defined as the fraction of an 
administered dose of medication that reaches the systemic circulation.  
 
When the drug is administered intravenously, its bioavailability is 100%. Where as when 
a drug is administered via other routes (such as oral route), its bioavailability gets 
decreased (due to incomplete absorption and first-pass metabolism). Bioavailability is an 
important tool essential in pharmacokinetics, and is considered to calculate dosages for 
non-intravenous routes of administration.  
 
Bioavailability reflects the extent of the systemic availability of the active therapeutic 
moiety and is generally assessed by measuring the ‘area under the plasma concentration 
time curve’ (AUC), the peak plasma concentration (Cmax) and the time to reach Cmax 
(Tmax). 
The extent of the systemic availability is determined by the extent of drug 
absorbed from the site of administration. For a drug that obeys linear 
pharmacokinetics, the AUC and Cmax values increase proportionately with 
the dose. Consequently, if two formulations / dosage form of the same drug 
exhibit comparative AUC values, they are considered to have similar systemic 
availability. The bioavailability of an oral dosage form or a drug is generally 
compared with an intravenous solution (100% standard), to determine the 
absolute bioavailability. 
 
2.2  Bioequivalence 
The absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives 
becomes available at the site of drug action when administered at the same molar dose 
under similar conditions in an appropriately designed study. 
On the basis of simple pharmacokinetic concepts and parameters, bioavailability and 
bioequivalence studies have been established as acceptable surrogates for expensive, 
complicated and lengthy clinical trials, and are used extensively worldwide to establish 
and ensure consistent quality and a reliable, therapeutically effective performance of 
marketed dosage forms. 
Bioequivalence gained increasing attention during the last 40 years after it became 
evident that generic product and innovator product, having the same amounts of the drug, 
may exhibit marked differences in their therapeutic responses.  
 
Studies to establish BE of a product are important elements in support of ANDAs, of 
generic drugs.  
 
Generic drug applications are termed "abbreviated" because they are generally not 
required to include preclinical (animal) and clinical (human) data to establish safety and 
effectiveness.  Instead, generic applicants must scientifically demonstrate that their 
product is bioequivalent (i.e., performs in the same manner as the innovator drug).  One 
way scientists demonstrate bioequivalence is to measure the time it takes the generic drug 
to reach the bloodstream of healthy volunteers.  This gives them the rate of absorption, or 
bioavailability, of the generic drug, which they can then compare to that of the innovator 
drug.  The generic version must deliver the same amount of active ingredients into a 
patient's bloodstream in the same amount of time as the innovator drug.  
 
Once bioequivalence is established between two products the concept of prescribability 
and switchability comes into picture. These are concepts about the ease with which the 
physician can prescribe the generic product or the innovator product depending on 
various factors. 
 
Drug prescribability is defined as the physician's choice for prescribing an appropriate 
drug product for his/her new patients between a brand-name drug product and a number 
of generic drug products of the brand-name product, which have been shown to be 
bioequivalent to the brand-name drug product. The underlying assumption of drug 
prescribability is that the brand-name drug product and its generic copies can be used 
interchangeably in terms of the efficacy and safety of the drug product. 
 
Drug switchability is related to the switch from a drug product (eg: a brand-name drug 
product) to an alternative drug product (eg: a generic copy of the brand-name drug 
product) within the same subject whose concentration of the drug product has been 
titrated to a steady, efficacious, and safe level. As a result, drug switchability is 
considered more critical than drug prescribability in the study of drug interchangeability 
for patients who have been on medication for a while. To assure drug switchability, it is 
recommended that bioequivalence be assessed within individual subjects. This type of 
bioequivalence is known as individual bioequivalence (IBE). 
 
Bioavailability and bioequivalence of drug products have emerged as critical issues in 
pharmacy and medicine during the last three decades. Concern about lowering health care 
costs has resulted in tremendous increase in the use of generic drug products; currently 
about one half of all prescriptions written are for drugs that can be substituted with a 
generic product. 
 
This phenomenal growth of the generic pharmaceutical industry and the abundance of 
multisource products have prompted some questions among many health professionals 
and scientists regarding the therapeutic equivalency of these products. Inherent in the 
currently accepted guidelines for product substitution is the assumption that a generic 
drug considered to be bioequivalent to a brand-name drug would elicit the same clinical 
effect. 
             
The goal of a BE study is to compare the two formulations of same drug by keeping the 
experimental design and the remaining factors constant.  
 
 The extent of the systemic availability is determined by the extent of drug absorbed from 
the site of administration. For a drug that obeys linear pharmacokinetics, the AUC and 
Cmax values increase proportionately with the dose. Consequently, if two formulations / 
dosage form of the same drug exhibit comparative AUC values, they are considered to 
have similar systemic availability. The bioavailability of an oral dosage form or a drug is 
generally compared with an intravenous solution (100% standard), to determine the 
absolute bioavailability. 
 
2.3 COMPARATIVE BIOAVAILABILITY3:  
A UNIVERSAL APPROACH:  
Most bioavailability studies, whether for a new or generic product, possess a 
common theme.  A test is conducted to identify the quantitative nature of a 
specific product comparison.  This comparison for a new drug may be, for 
example, to assess the  
Performance of an oral formulation relative to that of an intravenous dose, or 
perhaps the performance of a modified-release formulation in comparison to 
a conventional capsule.   
For a generic product, it is typically a comparison of a competitive 
formulation with a  
reference product.  Such commonality surrounding comparative 
bioavailability studies suggests a universal approach. 
 
  
 
•  From the Figure, the two primary metrics for such concentration versus 
time profiles are the area under the curve (AUC) and the maximum 
observed concentration (Cmax); the former customarily includes the 
AUC to the last sampling time in a trial (AUCt) and the extrapolated 
total AUC to time infinity (AUC∞). The time at which the maximum 
concentration is obtained (Tmax). After obtaining the profiles in a 
comparative trial, and Time infinity (AUC∞) is the extrapolated area 
based on the AUCt and the terminal constant (λz).       
      Peak concentration:  
Peak concentration should be assessed by measuring the peak drug 
concentration    (Cmax) obtained directly from the data without 
interpolation.  
• Total concentration:  
For single-dose studies, the measurement of total concentration should 
be: 
Area under the plasma/serum/blood concentration-time curve from time zero 
to time t (AUC0-t), where t is the last time point with measurable 
concentration for individual formulation. Area under the 
plasma/serum/blood concentration-time curve from time zero to time infinity 
(AUC0-), where AUC0- = AUC0-t + Ct/λz, Ct is the last measurable drug 
concentration and λz. Is the terminal or elimination rate constant calculated 
according to an appropriate method. The terminal half-life (t1/2) of the drug 
should also be reported. 
The following pharmacokinetic parameters are required for submission: 
z Plasma concentrations and time points  
z Subject, period, sequence, treatment  
z AUC0-t, AUC0-, Cmax, Tmax, λz, and t1/2.  
z Intersubject, intrasubject, and/or total variability, if available  
 
Bioequivalence gained increasing attention during the last 40 years after it became 
evident that generic product and innovator product, having the same amounts of the drug, 
may exhibit marked differences in their therapeutic responses.  
 
Situations in which bioequivalence studies are required 
• When significant changes are made in the manufacture of the 
marketed formulation, and  
• When a new generic formulation is tested against the innovator’s 
marketed product.  
 
Bioequivalence studies compare both the rate and extent of absorption of various 
multisource formulations with the innovator (reference) product, on the basis that if two 
formulations exhibit similar drug concentration-time profiles in the blood/plasma, they 
should exhibit similar therapeutic effects. 
 
Bioequivalent simply means that one brand or dosage form of a drug or supplement is 
equivalent to a reference brand or dosage form of the same drug or supplement in terms 
of various bioavailability parameters measured via in vivo testing in human subjects.  
 
A product can be either bio-equivalent or bio-in equivalent. A product cannot be more 
bio-equivalent or less bio-equivalent. 
2.4 General Concepts of Design and Conduct of Bioequivalence Studies4: 
 
The design and conduct of the study should follow Good Clinical 
Practice, including reference to an Ethics Committee. 
 
As recommended by the US FDA (1992), in most bioequivalence trials, 
a “test” formulation is compared with the standard / innovator “reference” 
formulation, in a group of normal, healthy subjects (18-55 yr), each of whom 
receive both the treatments alternately, in a crossover fashion (two-period, 
two-treatment crossover design), with the two phases of treatment separated 
by a “washout period” of generally a week’s duration, but may be longer (a 
minimum time equivalent to 5 half-lives) if the elimination half-life of the 
drug is very long. The treatment is assigned to each subject, randomly, but an 
equal number of subjects receive (Balanced) each treatment in each phase. 
Thus, in case of two treatments A and B, one group gets the treatment in the 
order AB and the second group in the reverse order BA. This is done to avoid 
the occurrence of possible sequence or period effects. A similar allocation is 
done in case of a three-treatment crossover design (three-period, three-
treatment crossover design). 
For several drugs a great inter-subject variability in clearance is 
observed. The intra-subject coefficient of variation (approximately 15%) is 
usually substantially smaller than that between subjects (approximately 
30%), and therefore, crossover designs are generally recommended for 
bioequivalence studies. 
The primary advantage of the crossover design is that since the 
treatments are compared on the same subject, the intersubject variability 
does not contribute to the error variability. If the drug under investigation 
and/or its metabolites has an extremely long half-life, a parallel group design 
may be indicated. In a parallel group design, subjects are divided randomly 
into groups, each group receiving one treatment only. Thus, each subject 
receives only one treatment. In a parallel design, although one does not have 
to worry about sequence, period or carry over effects, or dropouts during the 
study, the inter-subject variability being very high, the sensitivity of the test is 
considerably reduced, thus requiring a larger number of subjects compared 
to a crossover design, to attain the same sensitivity. 
 
Inherent in both the crossover and parallel designs are the three fundamental 
statistical concepts of study design, namely  
• Randomization  
• Replication and Error control.  
• Randomization 
It implies allocation of treatments to the subjects without selection bias. 
Consequently, randomization is essential to determine an unbiased estimate 
of the treatment effects. 
 
• Replication 
 It implies that a treatment is applied to more than one experimental 
unit (subject) to obtain more reliable estimates than is possible from a single 
observation and hence provides a more precise measurement of treatment 
effects. The number of replicates (sample size) required will depend upon the 
degree of differences to be detected and inherent variability of the data. 
Replication is used concomitantly with “Error control” to reduce the 
experimental error or error variability.   
Crossover design for two medications (T–test; R = reference): 
2x2 crossover design: 
This is a conventional not-replicated design with two formulations, two periods, two 
sequences, each individual is randomly assigned to RT or TR sequence in two dosage 
periods. That is, individuals assigned to RT (TR) sequence receive formulation R (T) in 
the first dosage period and formulation T (R) in the second dosage period. Randomization 
for a 2x2 crossover study may be carried out through tables of random numbers or 
randomization procedures implemented by statistical software. It is represented as 
follows: 
Period Sequence 
1 2 
1 R T 
2 T R 
 
Replicated crossover design: 
More commonly used replicated crossover designs to compare two 
formulations are:  
Four-sequence and two-period design (Balaam’s design): 
Period Sequence 
1 2 
1 T T 
2 R R 
3 R T 
4 T R 
 
Two-sequence and four-period design: 
 
Period Sequence 
1 2 3 4 
1 T R R T 
2 R T T R 
 
Four-sequence and four-period design: 
 
Period Sequence 
1 2 3 4 
1 T T R R 
2 R R T T 
3 T R R T 
4 R T T R 
 
 
Two-sequence and three-period design: 
 
Period Sequence 
1 2 3 
1 T R T 
2 R T R 
 
 
 
 
 
 
Crossover design for three medications (Williams’ design): 
(Williams’ design with T1 = test 1, T2 = test 2, R = reference) 
In order to compare three formulations of a drug, there are a total of three possible 
comparison pairs among formulations: formulation 1 versus formulation 2, formulation 1 
versus formulation 3, and formulation 2 versus formulation 3.  
 
Period Sequence 
1 2 3 
1 R T2 T1 
2 T1 R T2 
3 T2 T1 R 
4 T1 T2 R 
5 T2 R T1 
6 R T1 T2 
 
Crossover design for four medications (Williams’ design): 
This design is recommended for bioequivalence studies of formulations with modified-
release dosage or highly variable products (intra-individual variation coefficient ≥30%), 
including the quick-release, and modified-release ones and other oral administration 
products. 
The same test and reference formulation batches shall be used for this design for 
replicated administration. The periods shall be sufficiently spaced (washout) to assure 
non-existence of carryover effects. 
 
Period Sequence 
1 2 3 4 
1 R T3 T1 T2 
2 T1 R T2 T3 
3 T2 T1 T3 R 
4 T3 T2 R T1 
• Wash out period: 
Subsequent treatments should be separated by periods long enough to eliminate 
the previous dose before the next one (wash-out period). Sampling should be done long 
enough to cover at least 80% of the area under the plasma concentration curve as 
extrapolated to infinity. The extrapolation should be based on knowledge of the 
dominating elimination half-life.  
 
• Subjects: 
The number of subjects required is determined by the error variance associated 
with the primary characteristic to be studied (as estimated from a pilot experiment, from 
previous studies or from published data), by the significance level desired, and by the 
deviation from the reference product compatible with bioequivalence and with safety and 
efficacy. It should be calculated by appropriate methods and should not be smaller than 
12. The deviation allowable usually is 20%. The number of recruited subjects should 
always be justified. 
 
       Bioavailability studies generally will be performed with healthy volunteers. If 
feasible, they should belong to both sexes and be between 18 and 50 years old to 
minimize intra- and inter-individual variation subjects should be standardized as much as 
possible and acceptable. They should preferably be fasting at least 10 hours during the 
night before administration of the products or they should take a standard meal at a 
specified time before the treatment. Time and preferably composition of meals taken after 
the treatment should be standardized. Because fluid intake may profoundly influence 
gastric passage, it should be strictly standardized and specified. The subjects should not 
take other medicines during a suitable period before and during the study. They should 
preferably abstain from food and drinks, which may interact with circulatory, gastro-
intestinal, liver or renal function (e.g. alcoholic or xanthine-containing beverages). 
Preferably they should be non-smokers. If smokers are included they should be identified 
as such. In some cases (e.g. study of high clearance substances) even posture or physical 
activity may have to be standardized. 
 
• Reference and test product: 
All investigated products must have been prepared in accordance with GMP-rules. Batch 
control results of the test product should be reported. Generic products, being 
pharmaceutical equivalents or alternatives are normally compared with the corresponding 
form of a well-established “Innovator” medicinal product (reference product). The 
applicant should justify the choice of reference product. The test product will mostly 
originate from a test batch. After scale-up samples of the product the production batches 
should be compared with those of the test batch, and they should show the same 
dissolution rate “in vitro” in a discriminatory test. The study sponsor will have to retain a 
sufficient number of product samples for the accepted shelf life plus one year to allow 
repetition of “in vitro” and “in vivo” studies at the request of the regulatory authority. 
 
All investigated products must have been prepared in accordance with GMP-rules. Batch 
control results of the test product should be reported. Generic products, being 
pharmaceutical equivalents or alternatives are normally compared with the corresponding 
form of a well-established “Innovator” medicinal product (reference product). The 
applicant should justify the choice of reference product. The test product will mostly 
originate from a test batch. After scale-up samples of the product the production batches 
should be compared with those of the test batch, and they should show the same 
dissolution rate “in vitro” in a discriminatory test. The study sponsor will have to retain a 
sufficient number of product samples for the accepted shelf life plus one year to allow 
repetition of “in vitro” and “in vivo” studies at the request of the regulatory authority. 
 
• Data analysis: 
The aim of a bioequivalence study is to demonstrate equivalence within the 
acceptance range regarded as clinically relevant. The primary concern in bioequivalence 
assessment is to limit the risk of erroneously accepting bioequivalence. Only statistical 
procedures, which do not exceed the nominal risk of 5%, can be approved, and among 
them the one with the smallest risk of erroneously rejecting bioequivalence should be 
selected. 
In case of a parametric approach the inclusion of the classical 90% confidence 
interval for the chosen measure of relative bioavailability within the acceptance range 
(bioequivalence range) is the procedure of choice. This procedure is equivalent to the 
rejection of two one sided hypotheses concerning bioinequivalence at the nominal 5%-
level. According to present views concentrations and concentration-related characteristics 
(e.g. AUC, MRT) should preferably be tested after logarithmic transformation. If the 
assumption of a log normal (AUC, Cmax) distribution or normal (tmax) distribution in the 
parametric approach is doubtful, a corresponding non-parametric approach is 
recommended. This approach may also be chosen as the general statistical approach to 
evaluate all bioavailability characteristics throughout a given study. Assumptions on the 
design or statistical analysis should be discussed. 
 
• “In vitro” Dissolution 
The results of “in vitro” dissolution tests, obtained with the batches of test and 
reference products that are used in the bioavailability or bioequivalence study. The 
specifications for the “in vitro” dissolution of the product should be derived from the 
dissolution profile of the batch that was found to be bioavailability or bioequivalent. 
 
• Reporting 
The report of a bioavailability or bioequivalence study should give the complete 
documentation of its protocol, conduct and evaluation complying with GCP. This implies 
that the signature of the study monitor attests the authenticity of the whole of the report. 
The responsible investigators should sign for their respective sections of the report. 
Names and affiliations of the responsible investigators, site of the study and period of its 
execution should be stated. The names and batch numbers of the products used in the 
study as well as the composition(s) of the test product(s) should be given. In addition the 
applicant may submit a signed statement, confirming the identity of the test product with 
the product, which is submitted for registration. All results should be presented in a clear 
way. The way of calculating the characteristics used (e.g. AUC) from the raw data should 
be specified. Deletion of data should be justified. If results are calculated using 
pharmacokinetic models the model and the computing procedure used should be justified. 
 Individual plasma concentration/time curves should be drawn on a linear/linear, and 
facultative also on a linear/log scale. The report should contain individual data and 
results, it should also give the details, of dropped-out subjects.  
A representative number of chromatograms should be included. The analytical validation 
report should be reported.  
2.5 AN OVERVIEW OF THE DISEASE 
Epilepsy is a neurological condition that from time to time produces brief disturbances in 
the normal electrical functions of the brain. Normal brain function is made possible by 
millions of tiny electrical charges passing between nerve cells in the brain and to all parts 
of the body. When someone has epilepsy, this normal pattern may be interrupted by 
intermittent bursts of electrical energy that are much more intense than usual. They may 
affect a person's consciousness, bodily movements or sensations for a short time. 
 
These physical changes are called epileptic seizures. That is why epilepsy is sometimes 
called a seizure disorder. The unusual bursts of energy may occur in just one area of the 
brain (partial seizures), or may affect nerve cells throughout the brain (generalized 
seizures). Normal brain function cannot return until the electrical bursts subside. 
Conditions in the brain that produce these episodes may have been present since birth, or 
they may develop later in life due to injury, infections, structural abnormalities in the 
brain, exposure to toxic agents, or for reasons that are still not well understood. Many 
illnesses or severe injuries can affect the brain enough to produce a single seizure. When 
seizures continue to occur for unknown reasons or because of an underlying problem that 
cannot be corrected, the condition is known as epilepsy. Epilepsy affects people of all 
ages, all nations, and all races. Epilepsy can also occur in animals, including dogs, cats, 
rabbits, and mice. 
Epilepsy is a neurological disorder that affects people in every country throughout the 
world. Epilepsy is also one of the oldest conditions known to mankind. It is characterized 
by a tendency to recurrent seizures and it defined by two or more unprovoked seizures. 
A Seizure or convulsion is a brief period of unconsciousness or altered consciousness. It 
may be accompanied by one or more of the following symptoms: falling; muscle spasms; 
drooling or "frothing" at the mouth, loss of bladder or bowel control, a temporary halt in 
breathing.  
 
Seizures may occur in anyone, irrespective of the age. It can be a terrifying sight when a 
person suffers a seizure and most often the family members or attendants of the person do 
not know what to do. A seizure struck person does not respond. Panic and alarm are the 
first reactions but an understanding of the underlying mechanism can alleviate anxiety.   
 
 
 
 
CAUSES: 
 Figure-1 causes of epilepsy5 
Our brain is an enormously huge and complex network of electrical circuits. Seizures are 
the result of abnormal activity in one area of this circuit which causes abnormal currents 
to spread to the rest of the brain. The result is a seizure with its attendant physical and/or 
behavioral manifestations.  
 
Seizures are associated with many medical conditions. Most convulsions in infants and 
toddlers are caused by fever. Though they are terrifying to parents, these seizures are 
usually brief and rarely cause lasting damage. Seizures may also be caused by 
gastrointestinal disease, poisoning, head injury, brain disease such as a tumor, and rarely, 
breath-holding during a tantrum. Repeated convulsions might turn out to be an indicator 
to a chronic condition of epilepsy. 
 
 
Definition6 
“A seizure is a sudden change in behavior due to abnormal electrical activity in the 
brain”. A Seizure or convulsion is a brief period of unconsciousness or altered 
consciousness. It may be accompanied by one or more of the following symptoms: 
falling; muscle spasms; drooling or "frothing" at the mouth, loss of bladder or bowel 
control, a temporary halt in breathing.There are so many kinds of seizures that 
neurologists who specialize in epilepsy are still updating their thinking about how to 
classify them.  
 
Figure -2  Types of seizures5 
Usually, they classify seizures into two types, primary generalized seizures and partial 
seizures.  
The difference between these types is in how they begin: 
2.5.1 Primary generalized seizures 
Primary generalized seizures begin with a widespread electrical discharge that involves 
both sides of the brain at once. Hereditary factors are important in many of these seizures. 
2.5.2 Partial seizures 
Partial seizures begin with an electrical discharge in one limited area of the brain. Some 
are related to head injury, brain infection, stroke, or tumor, but in most cases the cause is 
unknown. 
One question that is used to further classify partial seizures is whether consciousness (the 
ability to respond and remember) is "impaired" or "preserved." The difference may seem 
obvious, but really there are many degrees of impairment or preservation of 
consciousness. Identifying certain seizure types and other characteristics of a person's 
epilepsy like the age at which it begins, for instance, allows doctors to classify some 
cases into epilepsy syndromes. This kind of classification helps us to know how long the 
epilepsy will last and the best way to treat it. 
 
 
Primary Generalized seizures are further classified into following types 
a) Absence seizures 
b) Atypical absence seizures 
c) Myoclonic seizures 
d) Atonic seizures 
e) Tonic seizures 
f) Clonic seizures 
g) Tonic-clonic seizures 
Partial Seizures are further classified into following types 
i. Simple partial seizures 
ii. Complex partial seizures 
iii. Secondarily generalized seizure 
Primary Generalized seizures 
a. Absence seizures: 
Usually less than 10 seconds, but it can be as long as 20 seconds. They begin and end 
suddenly. Absence seizures are brief episodes of staring. Another name for them is petit 
mal. During the seizure, awareness and responsiveness are impaired. People who have 
them usually don't realize when they've had one. There is no warning before a seizure, 
and the person is completely alert immediately afterward.                        
Simple absence seizures are just stares. Many absence seizures are considered as 
complex absence seizures, which mean that they include a change in muscle activity. The 
most common movements are eye blinks. Other movements include slight tasting 
movements of the mouth, hand movements such as rubbing the fingers together, and 
contraction or relaxation of the muscles. Complex absence seizures are often more than 
10 seconds long. 
Absence seizures usually begin between ages 4 and 14. The children who get them 
usually have normal development and intelligence. In nearly 70% of cases, absence 
seizures stop by age 18. Children who develop absence seizures before age 9 are much 
more likely to outgrow them than children whose absence seizures start after age 10. 
Children with absence seizures do have higher rates of behavioral, educational, and social 
problems. 
b. Atypical Absence 
Usually 5 to 30 seconds (commonly more than 10), with a gradual beginning and ending. 
Atypical means unusual or not typical. The person will stare (as they would in any 
absence seizure) but often is somewhat responsive. Eye blinking or slight jerking 
movements of the lips may occur. This behavior can be hard to distinguish from the 
person's usual behavior, especially in those with cognitive impairment. Unlike other 
absence seizures, these seizures usually cannot be produced by rapid breathing. 
They generally begin before age 6. Most of the children affected have below-average 
intelligence and other types of seizures that are difficult to control. Many have Lennox-
Gastaut syndrome. 
Atypical absence seizures usually continue into adulthood.  Sometimes ordinary behavior 
for these children will look like an atypical absence seizure. Daydreaming and 
inattentiveness can mimic these seizures. 
 
c. Myoclonic Seizures 
They're very brief jerks. Usually they don't last more than a second or two. There can be 
just one, but sometimes many will occur within a short time. 
The epileptic syndromes that most commonly include myoclonic seizures usually begin 
in childhood, but the seizures can occur at any age. Other characteristics depend on the 
specific syndrome. 
Myoclonic seizures are brief, shock-like jerks of a muscle or a group of muscles. "Myo" 
means muscle and "clonus" means rapidly alternating contraction and relaxation—jerking 
or twitching—of a muscle. Even people without epilepsy can experience myoclonus in 
hiccups or in a sudden jerk that may wake you up as you're just falling asleep. These 
things are normal. 
In epilepsy, myoclonic seizures usually cause abnormal movements on both sides of the 
body at the same time. They occur in a variety of epilepsy syndromes that have different 
characteristics: 
• Juvenile myoclonic epilepsy: The seizures usually involve the neck, shoulders, 
and upper arms. In many patients the seizures most often occur soon after waking 
up. They usually begin around puberty or sometimes in early adulthood in people 
with a normal range of intelligence. In most cases, these seizures can be well 
controlled with medication but it must be continued throughout life. 
• Lennox-Gastaut syndrome: This is an uncommon syndrome that usually includes 
other types of seizures as well. It begins in early childhood. The myoclonic 
seizures usually involve the neck, shoulders, upper arms, and often the face. They 
may be quite strong and are difficult to control. 
• Progressive myoclonic epilepsy: The rare syndromes in this category feature a 
combination of myoclonic seizures and tonic-clonic seizures. Treatment is usually 
not successful for very long, as the patient deteriorates over time. 
As mentioned, some episodes of myoclonus are normal. Some myoclonic seizures occur 
in reflex epilepsies, triggered by flashing lights or other things in the environment. 
 
 
 
d. Atonic Seizures 
Duration is less than 15 seconds. 
Muscle "tone" is the muscle's normal tension. "Atonic" means "without tone," so in an 
atonic seizure, muscles suddenly lose strength. The eyelids may droop, the head may nod, 
and the person may drop things and often falls to the ground. These seizures are also 
called "drop attacks" or "drop seizures." The person usually remains conscious. 
Another name for this type of seizure is "akinetic", which means "without 
movement."Atonic seizures often begin in childhood. They often last into adulthood. 
e. Tonic Seizures 
Usually less than 20 seconds. 
Muscle "tone" is the muscle's normal tension at rest. In a "tonic" seizure, the tone is 
greatly increased and the body, arms, or legs make sudden stiffening movements. 
Consciousness is usually preserved. Tonic seizures most often occur during sleep and 
usually involve all or most of the brain, affecting both sides of the body. If the person is 
standing when the seizure starts, he or she often will fall. 
They are particularly common in people who have the epilepsy syndrome called Lennox-
Gastaut syndrome, but they can occur in anyone. Tonic seizures in Lennox-Gastaut 
syndrome may become more difficult to control over time. Some patients do achieve a 
good outcome. Children with neurological impairments sometimes make movements that 
could be mistaken for tonic seizures. 
f. Clonic Seizures 
Clonic seizures consist of rhythmic jerking movements of the arms and legs, sometimes 
on both sides of the body. The length of time varies. 
"Clonus" means rapidly alternating contraction and relaxation of a muscle - in other 
words, repeated jerking. The movements cannot be stopped by restraining or 
repositioning the arms or legs. Clonic seizures are rare, however. Much more common 
are tonic-clonic seizures, in which the jerking is preceded by stiffening (the "tonic" part). 
Sometimes tonic-clonic seizures start with jerking alone. These are called clonic-tonic-
clonic seizures. 
Clonic seizures are not seen very often. They can occur at various ages, including in 
newborns. Brief and infrequent clonic seizures in infants usually disappear on their own 
within a short time. Other types may need prolonged treatment. 
Occasionally "jitteriness" in a young infant can be mistaken for a clonic seizure, 
especially if it is severe (during crying, for instance). Changing the position of the baby's 
arms or legs should reduce or stop jitteriness. The jittery infant also will be more alert 
than an infant who is having a clonic seizure. Children with neurological impairments 
sometimes have repetitive movements that could be mistaken for clonic seizures. 
g. Tonic-Clonic Seizures 
Generally, 1 to 3 minutes. A tonic-clonic seizure that lasts longer than 5 minutes probably 
calls for medical help. A seizure that lasts more than 30 minutes, or three seizures 
without a normal period in between, indicates a dangerous condition called convulsive 
status epilepticus. This requires emergency treatment. 
This type is what most people think of when they hear the word "seizure." An older term 
for them is "grand mal." As implied by the name, they combine the characteristics of 
tonic seizures and clonic seizures. The tonic phase comes first. All the muscles stiffen. 
Air being forced past the vocal cords causes a cry or groan. The person loses 
consciousness and falls to the floor. The tongue or cheek may be bitten, so bloody saliva 
may come from the mouth. The person may turn a bit blue in the face. After the tonic 
phase comes the clonic phase: The arms and usually the legs begin to jerk rapidly and 
rhythmically, bending and relaxing at the elbows, hips, and knees. After a few minutes, 
the jerking slows and stops. Bladder or bowel control sometimes is lost as the body 
relaxes. Consciousness returns slowly, and the person may be drowsy, confused, agitated, 
or depressed. They affect both children and adults. 
For children who have had a single tonic-clonic seizure, the risk that they will have more 
seizures depends on many factors. Some children will outgrow their epilepsy. Often, 
tonic-clonic seizures can be controlled by seizure medicines. Some nonepileptic 
(psychogenic) seizures resemble tonic-clonic seizures. The surest way to tell the 
difference is with video-EEG monitoring. In some cases, the same person may have both 
tonic-clonic and nonepileptic seizures. 
People who faint sometimes develop tonic or clonic movements. These movements are 
rarely as intense or prolonged as a tonic-clonic seizure. 
PARTIAL SEIZURES 
i. Simple Partial Seizures 
Duration is usually less than 2 minutes. 
They are remarkably different from person to person, depending on the part of the brain 
where they begin. The one thing they all have in common is that the person remains alert 
and can remember what happens. Here are a couple of experiences: 
• "It is a pressure that starts in my stomach, then rises to my chest and throat. 
When it reaches my chest, I smell an unpleasant odor of something burnt. At the 
same time I feel anxious." 
Sometimes the seizure activity spreads to other parts of the brain, so another type of 
seizure follows the simple partial seizure. This can be a complex partial seizure or a 
secondarily generalized seizure. 
Doctors often divide simple partial seizures into categories depending on the type of 
symptoms the person experiences: 
Motor seizures: 
These cause a change in muscle activity. For example, a person may have abnormal 
movements such as jerking of a finger or stiffening of part of the body. These movements 
may spread, either staying on one side of the body (opposite the affected area of the 
brain) or extending to both sides. Other examples are weakness, which can even affect 
speech, and coordinated actions such as laughter or automatic hand movements. The 
person may or may not be aware of these movements. 
Sensory seizures: 
These cause changes in any one of the senses. People with sensory seizures may smell or 
taste things that aren't there; hear clicking, ringing, or a person's voice when there is no 
actual sound; or feel a sensation of "pins and needles" or numbness. Seizures may even 
be painful for some patients. They may feel as if they are floating or spinning in space. 
They may have visual hallucinations, seeing things that aren't there (a spot of light, a 
scene with people). They also may experience illusions—distortions of true sensations. 
For instance, they may believe that a parked car is moving farther away, or that a person's 
voice is muffled when it's actually clear. 
Autonomic seizures: 
These cause changes in the part of the nervous system that automatically controls bodily 
functions. These common seizures may include strange or unpleasant sensations in the 
stomach, chest, or head; changes in the heart rate or breathing; sweating; or goose bumps. 
Psychic seizures: 
These seizures change how people think, feel, or experience things. They may have 
problems with memory, garbled speech, and an inability to find the right word, or trouble 
understanding spoken or written language. They may suddenly feel emotions like fear, 
depression, or happiness with no outside reason. Some may feel as though they are 
outside their body or may have feelings of déja vu ("I've been through this before") or 
jamais vu ("This is new to me"— even though the setting is really familiar). 
Anybody can get them. They may be more likely in people who have had a head injury, 
brain infection, stroke, or brain tumor but most of the time the cause is unknown. 
Medical disorders such as, stomach disorders or a pinched nerve can cause some similar 
symptoms. Hallucinations can accompany psychiatric illness or the use of certain drugs. 
And some symptoms (such as déja vu) are experienced by almost everyone at some time. 
Whether the symptoms represent simple partial seizures depends on how often they occur 
and whether they are associated with other episodic changes or other seizure types. 
ii. Complex Partial Seizures 
They usually last between 30 seconds to 2 minutes. Afterward, the person may be tired or 
confused for about 15 minutes and may not be fully normal for hours. 
These seizures usually start in a small area of the temporal lobe or frontal lobe of the 
brain. They quickly involve other areas of the brain that affect alertness and awareness. 
So even though the person's eyes are open and they may make movements that seem to 
have a purpose, in reality "nobody's home." If the symptoms are subtle, other people may 
think the person is just daydreaming. 
Some people can have seizures of this kind without realizing that anything has happened. 
Because the seizure can wipe out memories of events just before or after it, however, 
memory lapses can be a problem. 
Some of these seizures (usually ones beginning in the temporal lobe) start with a simple 
partial seizure. Also called an aura, this warning seizure often includes an odd feeling in 
the stomach. Then the person loses awareness and stares blankly. Most people move their 
mouth, pick at the air or their clothing, or perform other purposeless actions. These 
movements are called "automatisms" (aw-TOM-ah-TIZ-ums). Less often, people may 
repeat words or phrases, laugh, scream, or cry. Some people do things during these 
seizures that can be dangerous or embarrassing, such as walking into traffic or taking 
their clothes off. These people need to take precautions in advance. 
Complex partial seizures starting in the frontal lobe tend to be shorter than the ones from 
the temporal lobe. The seizures that start in the frontal lobe are also more likely to 
include automatisms like bicycling movements of the legs or pelvic thrusting. Some 
complex partial seizures turn into secondarily generalized seizures. 
Anybody can get them. They may be more likely in people who have had a head injury, 
brain infection, stroke, or brain tumor but most of the time the cause is unknown. 
As for many other kinds of seizures, the outlook depends on whether the cause is known. 
They may be outgrown or controlled with medication. If medication is not effective, 
some can be eliminated by epilepsy surgery. 
iii. Secondarily Generalized Seizures 
Seizures of this kind start as a partial seizure—that is, they start in one limited area of the 
brain. The forms they take vary as much as other partial seizures. But then (sometimes so 
quickly that the partial seizure is hardly noticed) the seizure spreads throughout the brain, 
becoming "generalized." 
The generalized, convulsive phase of these seizures usually lasts no more than a few 
minutes, the same as primary generalized seizures. The preceding partial seizure is 
usually not very long. Sometimes this part is so brief that it is hard to detect. 
These seizures are called "secondarily generalized" because they only become 
generalized (spread to both sides of the brain) after the initial or "primary" event, a partial 
seizure, has already begun. They happen when a burst of electrical activity in a limited 
area (the partial seizure) spreads throughout the brain. Sometimes the person does not 
recall the first part of the seizure. These seizures occur in more than 30% of people with 
partial epilepsy. They can affect people of all ages who have partial seizures. 
Many seizures of this kind can be controlled with medication. If a person has tonic-clonic 
seizures that are not well controlled with medication, the doctor should investigate to see 
whether they might be secondarily generalized seizures that begin in a limited area of the 
brain. If they are, surgery could be an option. 
It may be difficult to distinguish these seizures from primary generalized tonic-clonic 
seizures, especially if they occur during sleep or are not witnessed by anyone else. Most 
convulsive seizures during sleep are secondarily generalized seizures that do begin as 
partial seizures. 
2.6 Epidemiology: 
Epilepsy knows no geographical, racial or social boundaries. It occurs in men and women 
and can begin at any age, but is most frequently diagnosed in infancy, childhood, 
adolescence and old age. Anyone can be affected by seizures. In fact, up to 5% of the 
world's population may have a single seizure at some time in their lives, but a diagnosis 
of epilepsy is reserved for those who have recurring seizures, at least two unprovoked 
ones. 
Prevalence 
The prevalence of a disorder is the proportion of a population with that disorder at a 
given point in time. From many studies around the world it has been estimated that the 
mean prevalence of active epilepsy (i.e. continuing seizures or the need for treatment) is 
approximately 8.2 per 1,000 of the general population. However, this may be an 
underestimate as some studies in developing countries (such as Colombia, Ecuador, 
India, Liberia, Nigeria, Panama, United Republic of Tanzania and Venezuela) suggest a 
prevalence of more than 10 per 1,000. 
Thus, it is likely that around 50 million people in the world have epilepsy at any one 
time. The lifetime prevalence of epilepsy (i.e. the number of people presently in the 
world who have epilepsy now or have had it in the past or will experience it in the future) 
is approximately 100 million people. 
 Incidence 
The incidence of a disorder is the number of new cases at a given time. Studies in 
developed countries suggest an annual incidence of epilepsy of approximately 50 per 
100,000 of the general population. However, studies in developing countries suggest that 
this figure is nearly double that at 100 per 100,000. 
One of the main reasons for the higher incidence of epilepsy in developing countries is 
the higher risk of experiencing a condition which can lead to permanent brain damage. 
These conditions include 1neurocysticercosis, meningitis, malaria, pre and perinatal 
complications and malnutrition. 
Mortality 
Epilepsy is associated with an increased risk of mortality. Death may be related to: 
• An underlying brain disease, such as a tumor or infection. 
• Seizures in dangerous circumstances, leading to drowning, burns or head injury. 
• Status epilepticus. 
• Sudden and unexplained causes or a possible respiratory or cardio-respiratory 
arrest during a seizure. 
• Suicide.  
 
  
Diagnosis 
A seizure disorder can be diagnosed when people have at least two unprovoked seizures 
that occur at different times. The diagnosis is based on symptoms and the observations of 
eyewitnesses. Symptoms that suggest a seizure include loss of consciousness, muscle 
spasms that shake the body, loss of bladder control, sudden confusion, and inability to 
pay attention. However, seizures cause such symptoms much less often than most people 
think. A brief loss of consciousness is more likely to be fainting (syncope—see Low 
Blood Pressure: Fainting) than a seizure. 
An eyewitness report of the episode can be very helpful to doctors. An eyewitness can 
describe exactly what happened, whereas people who have an episode usually cannot. 
Doctors need to have an accurate description, including the following:  
• How fast the episode started 
• Whether it involved abnormal muscle movements (such as spasms of the head, 
neck, or facial muscles), tongue biting, drooling, loss of bladder control, or 
muscle stiffening 
• How long it lasted 
• How quickly the person recovered 
Although eyewitnesses may be too frightened during the seizure to remember all details, 
whatever they can remember can help. If possible, how long a seizure lasts should be 
timed with a watch or other device. Seizures that last only 1 or 2 minutes can seem to go 
on forever. 
There is a need to know what people experienced before the episode: whether they had a 
premonition or warning that something unusual was about to happen and whether 
anything, such as certain sounds or flashing lights, seemed to trigger the episode. Doctors 
ask whether people have had a disorder that can cause seizures (such as a brain infection) 
or a head injury. Doctors also ask about which drugs (including alcohol) people are 
taking or have recently stopped. A thorough physical examination is done. It may provide 
clues to the cause of the symptoms.        
People are usually evaluated in an emergency department. If a seizure disorder has 
already been diagnosed and people have completely recovered, they may be evaluated in 
a doctor's office. 
Once a seizure is diagnosed, more tests are usually needed to identify the cause. People 
known to have a seizure disorder may not need additional tests. In others, blood tests are 
often done to measure the levels of substances such as sugar, calcium, sodium, and 
magnesium and to determine whether the liver and kidneys are functioning normally. A 
sample of urine may be analyzed to check for recreational drugs that may not be reported. 
Such drugs can trigger a seizure. Electrocardiography may be done to check for an 
abnormal heart rhythm. Because an abnormal heart rhythm can greatly reduce blood flow 
to the brain, it can trigger loss of consciousness and occasionally a seizure or symptoms 
that resemble a seizure. 
Computed tomography (CT) is usually done promptly to check for bleeding, tumors, and 
other structural damage to brain tissue (for example, by a stroke). If results are negative, 
magnetic resonance imaging (MRI) is usually done later. It provides detailed images of 
abnormalities and can detect most neurologic disorders. 
Electroencephalography (EEG) can help confirm the diagnosis. EEG is a painless, safe 
procedure that records electrical activity in the brain. Doctors examine the recording 
(electroencephalogram) for evidence of abnormal electrical discharges. Because the 
recording time is limited, EEG can miss abnormalities, and results may be normal, even 
in people who have a seizure disorder. EEG is sometimes scheduled after people have 
been deprived of sleep for 18 to 24 hours because lack of sleep makes abnormal 
discharges more likely to occur. 
Brain Activity during a Seizure 
An electroencephalogram (an EEG) is a recording of the brain's electrical activity. The 
procedure is simple and painless. About 20 small adhesive electrodes are placed on the 
scalp, and the brain's activity is recorded under normal conditions. Then the person is 
exposed to various stimuli, such as bright or flashing lights, to try to provoke a seizure. 
During a seizure, electrical activity in the brain accelerates, producing a jagged wave 
pattern. Such recordings of brain waves help identify a seizure disorder. Different types 
of seizures have different wave patterns. 
 
If the diagnosis is still uncertain, specialized tests, such as video-EEG monitoring, can be 
done at an epilepsy center. For this test, people are admitted to a hospital for 2 to 7 days, 
and EEG is done while they are video-taped. If people are taking an anticonvulsant, it is 
often stopped to increase the likelihood of a seizure. If a seizure occurs, doctors compare 
the EEG recording with the video recording of the seizure. They may then be able to 
identify the type of seizure and the area of the brain where the seizure began. 
Treatment 
If the cause can be identified and eliminated, no additional treatment is necessary. For 
example, if a low blood sugar (glucose) level (hypoglycemia—see Hypoglycemia) 
caused the seizure, glucose is given, and the disorder causing the low level is treated. 
Other treatable causes include an infection, certain tumors, and an abnormal sodium 
level. 
If people have a seizure disorder, general measures plus drugs are usually sufficient. If 
drugs are ineffective, surgery may be recommended. 
General Measures: Exercise is recommended and social activities are encouraged. 
However, people who have a seizure disorder may have to make some adjustments. For 
example, they should eliminate or limit their consumption of alcoholic beverages and 
should not use recreational drugs. They should refrain from activities in which a sudden 
loss of consciousness could result in serious injury. For example, they should not bathe in 
a bathtub, climb, swim, or operate power tools. After seizures are controlled (typically for 
at least 6 months), they can do these activities if adequate precautions are taken. For 
example, they should swim only when lifeguards are present. In most states, laws prohibit 
people with a seizure disorder from driving until they have been free of seizures for at 
least 6 months to 1 year. 
A family member or close friend should be trained to help if a seizure occurs. Attempting 
to put an object (such as a spoon) in the person's mouth to protect the person's tongue 
should not be tried. Such efforts can do more harm than good. The teeth may be 
damaged, or the person may bite the helper unintentionally as the jaw muscles contract. 
However, helpers should do the following during a seizure:  
• Protect the person from falling 
• Loosen clothing around the neck 
• Place a pillow under the head 
If a pillow is unavailable, helpers can put their foot or place an item of clothing under the 
person's head. 
People who lose consciousness should be rolled onto one side to ease breathing. People 
who have had a seizure should not be left alone until they have awakened completely, are 
no longer confused, and can move about normally. Usually, their doctor should be 
notified. 
Anticonvulsants: These drugs reduce the risk of having another seizure. Usually, they are 
prescribed only for people who have had more than one seizure, unless the cause has 
been identified and completely eliminated. They are usually not prescribed when people 
have had only one generalized seizure. Most anticonvulsants are taken by mouth. 
Anticonvulsants can completely prevent generalized seizures in about one third of people 
who have them and greatly reduce the frequency of seizures in another third. Almost two 
thirds of people who respond to anticonvulsants can eventually stop taking them without 
having a relapse. However, anticonvulsants are ineffective in about 10 to 20% of people 
with a seizure disorder. These people are referred to a seizure center and evaluated for 
surgery. 
There are many different types of anticonvulsants. Which one is effective depends on the 
type of seizure and the response to it. For most people, taking one anticonvulsant, usually 
the first or second one tried, controls seizures. If seizures recur, different anticonvulsants 
are tried. Determining which anticonvulsant is effective may take several months. Some 
people have to take several drugs, which increases the risk of side effects. Some 
anticonvulsants are not used alone but only with other anticonvulsants. 
Doctors take care to determine the appropriate dose of an anticonvulsant for each person. 
The best dose is the smallest dose that stops all seizures while having the fewest side 
effects. Doctors ask people about side effects, and then adjust the dose if needed. 
Sometimes doctors also measure the level of anticonvulsant in the blood. Anticonvulsants 
should be taken just as prescribed. People who take anticonvulsants to control seizures 
should see a doctor regularly for dose adjustment and should always wear a Medic Alert 
bracelet inscribed with the type of seizure disorder and the drug being taken. 
Anticonvulsants can interfere with the effectiveness of other drugs, and vice versa. 
Consequently, people should make sure their doctor knows all the drugs they are taking 
before they start taking anticonvulsants. They should also talk to their doctor and possibly 
their pharmacist before they start taking any other drugs, including over-the-counter 
drugs. 
After seizures are controlled, people take the anticonvulsant until they have been seizure-
free for at least 2 years. Then, the dose of the drug may be decreased gradually, and the 
drug eventually stopped. If a seizure recurs after the anticonvulsant is stopped, people 
may have to take an anticonvulsant indefinitely. Seizures usually recur within 2 years if 
they are going to. A recurrence is more likely in people who have had any of the 
following:  
• A seizure disorder since childhood 
• The need to take more than one anticonvulsant to be seizure-free 
• Seizures while taking an anticonvulsant 
• Partial or myoclonic seizures 
• Abnormal EEG results within the previous year 
Anticonvulsants, although very effective, may have side effects. Many cause drowsiness, 
but some may make children hyperactive. Blood tests are done periodically to determine 
whether an anticonvulsant is impairing kidney or liver function or reducing the number of 
blood cells. People taking anticonvulsants should be aware of possible side effects and 
should consult their doctor at the first sign of side effects.  
For women who have a seizure disorder and are pregnant, taking an anticonvulsant 
increases the risk of miscarrying or of having a baby with a birth defect. 
 However, stopping the anticonvulsant may be more harmful to the woman and the baby. 
Having a generalized seizure during pregnancy can injure or kill the fetus. All women 
who are of childbearing age and take an anticonvulsant should take folate supplements to 
reduce the risk of having a baby with a birth defect. 
Emergency Treatment: Emergency treatment is required for status epilepticus and 
seizures that last more than 5 minutes. Large doses of one or more anticonvulsants are 
given intravenously as quickly as possible. Measures to prevent injuries are taken during 
the prolonged seizure. People are monitored closely to make sure breathing is adequate. 
If it is not, a tube is inserted to help with breathing—a procedure called intubation. If 
seizures persist, a general anesthetic is given to stop them. 
 
 
 
 
 
 Present global anti-epileptic market7 
 
 
 
 
 
 
 
 
  
2.7 Marketed Drugs Used to Treat Seizures7 
Table - I 
Brand Name Drug Use 
Diamox Acetazolamide 
Absence seizures when other 
anticonvulsants are ineffective. 
Tegretol Carbamazepine 
Effective against generalised tonic clonic 
and partial seizures. Ineffective against 
absences.  
Frisium: Tablets 10mg Clobazam 
Effective against generalised tonic clonic 
and partial seizures, but tolerance develops 
in about one third of children 
Rivotril: Tablets 0.5mg, 
2mg. 
Clonazepam 
Effective against generalised tonic clonic 
and partial seizures, absences, myoclonic 
seizures, Lennox-Gastaut syndrome, 
infantile spasms and status epilepticus. 
Emeside: Syrup 
250mg/5mL. 
Zarontin: Syrup 
250mg/5mL. 
Ethosuximide 
Effective against generalised absences. May 
be used for epilepsies with similar EEG 
changes to absences 
Neurontin:  Gabapentin Recommended in partial seizures where 
Tablets 600mg, 800mg. 
Capsules 100mg, 300mg, 
previous treatment has been ineffective.  
Lamictal: Tablets 25mg, 
50mg, 100mg, 200mg. 
Dispersible tablets 2mg 
5mg, 25mg, 100mg 
Lamotrigine 
Effective against partial, absence, 
generalised tonic clonic seizures and 
Lennox-Gastaut syndrome. 
Keppra: Tablets 250mg, 
500mg, 1000mg. Oral 
solution 100mg/ml. 
Levetiracetam 
Can be used in children with partial or 
generalised seizures, over 4 years of age. 
Suspension 2.5mg/5ml Nitrazepam Infantile spasms. 
Trileptal: Tablets 150mg, 
300mg, 
Oxcarbazepine 
Partial and generalised seizures. 
Epanutin: Capsules 25mg, 
50mg, 100mg, 300mg. 
Chewable Infatabs 50mg. 
Suspension 30mg/5mL. 
Phenytoin 
Effective against generalised tonic clonic 
and partial seizures. Status epilepticus. 
Blood testing is essential when using 
phenytoin as the relationship between dose 
and blood level is complex. 
Mysoline: Tablets 250mg. 
 
Primidone 
Partial and generalised tonic clonic seizures.
Sabril: Tablets 500mg. 
Powder sugar free 500mg 
per sachet. 
 
Vigabatrin 
Can be considered for resistant partial 
seizures if visual fields can be monitored. 
First line for infantile spasms. May worsen 
absences and myoclonic seizures. 
 
Topamax: Tablets 25mg, 
50mg, 100mg, 200mg. 
Sprinkle capsules 15mg, 
25mg, 50mg. 
Topiramate Recommended in partial and generalised 
seizures. Severe myoclonic epilepsy in 
infancy. For children over 2 years old. 
Gabitril: Tablets 5mg, 
10mg, 15mg Tiagabine 
Recommended in partial seizures when 
previous treatment has been ineffective. 
May make myoclonic seizures worse 
Epilim: Tablets 200mg, 
500mg. Crushable tablets 
100mg.  
Liquid sugar free 
200mg/5mL. Syrup 
200mg/5mL. 
Epilim Chrono: Tablets 
200mg, 300mg, 500mg. 
Sodium valproate 
Effective against generalised tonic clonic 
and partial seizures and absences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 OBJECTIVES OF THE STUDY 
 
The following are objectives of the study 
 
¾ To assess the bioequivalence of the test product ‘T’ and compare with the 
reference product ‘R’ in 14 normal healthy male adult human subjects under 
fasting conditions. 
 
¾ To monitor adverse events and ensure the safety of subjects. 
 
¾ To investigate the source of observed variability in the Cmax of the test drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. DRUG REVIEW8 
4.1 Description  
Chemical name: 5-ethyldihydro-5-phenyl-4, 6 (1H, 5H) pyrimidinedione. 
Structural formula: 
 
 
 
Primidone is a white, crystalline, highly stable substance, M.P. 279-284°C. It is poorly 
soluble in water (60 mg per 100 mL at 37°C) and in most organic solvents. It possesses 
no acidic properties, in contrast to its barbiturate analog. 
Each tablet, for oral administration, contains 50 mg Primidone. In addition, each tablet 
contains the following inactive ingredients: colloidal silicon dioxide, ocusate sodium, 
magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium starch glycolate 
and stearic acid. 
4.2 Pharmacokinetic profile 
Absorption 
Readily absorbs from the GI tract. T max is 3 h (Primidone) and 7 to 8 h (Phenobarbital 
and phenylethylmalonamide [PEMA] metabolites). Bioavailability is 90% to 100%. 
Distribution 
Protein binding is negligible for Primidone and PEMA; approximately 50% 
(Phenobarbital). Distributes in to breast milk. Vd is 0.64 to 0.86 L/kg. 
 
Metabolism 
Primidone converts to Phenobarbital and phenylethylmalonamide (PEMA). PEMA is the 
major metabolite and is less active than Phenobarbital. It is still unknown which exact 
cytochrome P450 enzymes are responsible. The rate of Primidone metabolism was 
greatly accelerated by Phenobarbital pretreatment, moderately accelerated by Primidone 
pretreatment, and reduced by PEMA pretreatment. The rate of metabolism of Primidone 
into Phenobarbital was inversely related to age; the highest rates were in the oldest 
patients (the maximum age being 55).  
Elimination 
Excreted in the urine (40% as unchanged and remainder excreted as metabolites). Plasma 
t ½ is 5 to 15 h (Primidone), 10 to 18 h (PEMA), and 53 to 140 h (Phenobarbital). 
4.3 Pharmacodynamic profile9 
Primidone is a barbiturate with anticonvulsant properties. Primidone, either alone or used 
concomitantly with other anticonvulsants, is indicated in the control of grand mal, 
psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to 
other anticonvulsant therapy. Primidone raises electro- or chemoshock seizure thresholds 
or alters seizure patterns in experimental animals. Primidone per se has anticonvulsant 
activity as do its two metabolites, Phenobarbital and phenylethylmalonamide (PEMA). In 
addition to its anticonvulsant activity, Primidone potentiates that of Phenobarbital in 
experimental animals.  
 
Primidone is a GABA receptor agonist. The mechanism of PRIMIDONE antiepileptic 
action is exactly not known. 
   
Indications and Usage 
 
Primidone indicated in the control of grand mal, psychomotor, and focal epileptic 
seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. 
 
 
Adverse Events  
The most common events observed in clinical trials with Primidone that ataxia, vertigo, 
nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, diplopia, 
nystagmus, and drowsiness. 
 
 
4.4 Drug Interaction profile 
 
Induces CYP1A2 (strong), 2B6 (strong), 2C8/9 (strong), 3A4 (strong)  
Acetaminophen: Primidone may enhance the hepatotoxic potential of acetaminophen 
overdoses.  
Antiarrhythmics: Primidone may increase the metabolism of antiarrhythmics, 
decreasing their clinical effect; includes disopyramide, propafenone, and quinidine.  
Anticonvulsants: Primidone may increase the metabolism of anticonvulsants; includes 
ethosuximide, felbamate (possibly), lamotrigine, phenytoin, tiagabine, topiramate, and 
zonisamide; does not appear to affect gabapentin or levetiracetam. 
Antineoplastics: Limited evidence suggests that enzyme-inducing anticonvulsant 
therapy may reduce the effectiveness of some chemotherapy regimens (specifically in 
ALL); teniposide and methotrexate may be cleared more rapidly in these patients.  
Antipsychotics: Primidone may enhance the metabolism (decrease the efficacy) of 
antipsychotics; monitor for altered response; dose adjustment may be needed.  
Beta-blockers: Metabolism of beta-blockers may be increased and clinical effect 
decreased; atenolol and nadolol are unlikely to interact given their renal elimination.  
Calcium channel blockers: Primidone may enhance the metabolism of calcium channel 
blockers, decreasing their clinical effect.  
Chloramphenicol: Primidone may increase the metabolism of chloramphenicol and 
chloramphenicol may inhibit barbiturate metabolism; monitor for altered response.  
Cimetidine: Primidone may enhance the metabolism of cimetidine, decreasing its 
clinical effect. 
CNS depressants: Sedative effects and/or respiratory depression with Primidone may be 
additive with other CNS depressants; monitor for increased effect. Includes ethanol, 
sedatives, antidepressants, narcotic analgesics, and benzodiazepines.  
Corticosteroids: Primidone may enhance the metabolism of corticosteroids, decreasing 
their clinical effect. 
Cyclosporine: Levels may be decreased by Primidone.  
CYP1A2 substrates: Primidone may decrease the levels/effects of CYP1A2 substrates. 
Example substrates include aminophylline, estrogens, fluvoxamine, mirtazapine, 
ropinirole, and theophylline..  
CYP2B6 substrates Primidone may decrease the levels/effects of CYP2B6 substrates. 
Example substrates include bupropion, efavirenz, promethazine, selegiline, and sertraline.  
CYP2C8/9 substrates: PRIMIDONE may decrease the levels/effects of CYP2C8/9 
substrates. Example substrates include amiodarone, fluoxetine, glimepiride, glipizide, 
losartan, nateglinide, phenytoin, pioglitazone, rosiglitazone, sertraline, sulfonamides, 
warfarin, and zafirlukast.  
CYP3A4 substrates: PRIMIDONE may decrease the levels/effects of CYP3A4 
substrates. Example substrates include benzodiazepines, calcium channel blockers, 
clarithromycin, cyclosporine, erythromycin, estrogens, mirtazapine, nateglinide, 
nefazodone, nevirapine, protease inhibitors, tacrolimus, and venlafaxine.  
Doprimidonecycline: PRIMIDONE may enhance the metabolism of 
doprimidonecycline, decreasing its clinical effect; higher dosages may be required  
Estrogens: PRIMIDONE may increase the metabolism of estrogens and reduce their 
efficacy.  
Felbamate may inhibit the metabolism of PRIMIDONE and PRIMIDONE may 
increase the metabolism of felbamate.  
Griseofulvin: PRIMIDONE may impair the absorption of griseofulvin, and griseofulvin 
metabolism may be increased by PRIMIDONE, decreasing clinical effect.  
Guanfacine: Effect may be decreased by PRIMIDONE.  
Immunosuppressants: PRIMIDONE may enhance the metabolism of 
immunosuppressants, decreasing its clinical effect; includes both cyclosporine and 
tacrolimus.  
Loop diuretics: Metabolism may be increased and clinical effects decreased; established 
for furosemide, effect with other loop diuretics not established.  
MAO inhibitors: Metabolism of PRIMIDONE may be inhibited, increasing clinical 
effect or toxicity of the PRIMIDONE.  
Methadone: PRIMIDONE may enhance the metabolism of methadone resulting in 
methadone withdrawal.  
Methoprimidoneflurane: PRIMIDONE may enhance the nephrotoxic effects of 
methoprimidoneflurane.  
Oral contraceptives: PRIMIDONE may enhance the metabolism of oral contraceptives, 
decreasing their clinical effect; an alternative method of contraception should be 
considered.  
Theophylline: PRIMIDONE may increase metabolism of theophylline derivatives and 
decrease their clinical effect.  
Tricyclic antidepressants: PRIMIDONE may increase metabolism of tricyclic 
antidepressants and decrease their clinical effect; sedative effects may be additive.  
Valproic acid: Metabolism of PRIMIDONE may be inhibited by valproic acid; monitor 
for excessive sedation; a dose reduction may be needed.  
Warfarin: PRIMIDONE inhibit the hypoprothrombinemic effects of oral anticoagulants 
via increased metabolism; this combination should generally be avoided. 
Contraindications: 
PRIMIDONE is contraindicated in:  
1) Patients with porphyria  
2) Patients with clinically significant hypersensitivity to the drug or any of the 
components contained in the formulation. 
 
4.5 Therapeutic Dosage 
 
Therapeutic dose of PRIMIDONE ranges from 50 mg to 250 mg depending upon the 
indication and the severity of underlying condition. 
 
 
Precautions 
The abrupt withdrawal of antiepileptic medication may precipitate status epilepticus. 
The therapeutic efficacy of a dosage regimen takes several weeks before it can be 
assessed. 
Usage in Pregnancy 
The effects of PRIMIDONE in human pregnancy and nursing infants are unknown. 
Recent reports suggest an association between the use of anticonvulsant drugs by women 
with epilepsy and an elevated incidence of birth defects in children born to these women. 
Data are more extensive with respect to diphenylhydantoin and Phenobarbital, but these 
are also the most commonly prescribed anticonvulsants; less systematic or anecdotal 
reports suggest a possible similar association with the use of all known anticonvulsant 
drugs. 
The reports suggesting an elevated incidence of birth defects in children of drug treated 
epileptic women cannot be regarded as adequate to prove a definite cause and effect 
relationship. 
There are intrinsic methodologic problems in obtaining adequate data on drug 
teratogenicity in humans; the possibility also exists that other factors leading to birth 
defects, e.g., genetic factors or the epileptic condition itself may be more important than 
drug therapy. The great majority of mothers on anticonvulsant medication deliver normal 
infants. 
It is important to note that anticonvulsant drugs should not be discontinued in patients in 
whom the drug is administered to prevent major seizures because of the strong possibility 
of precipitating status epilepticus with attendant hypoxia and threat to life. In individual 
cases where the severity and frequency of the seizure disorders are such that the removal 
of medication does not pose a serious threat to the patient, discontinuation of the drug 
may be considered prior to and during pregnancy, although it cannot be said with any 
confidence that even minor seizures do not pose some hazard to the developing embryo 
or fetus. 
The prescribing physician will wish to weigh these considerations in treating or 
counseling epileptic women of childbearing potential. 
Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has 
been described in newborns whose mothers were taking PRIMIDONE and other 
anticonvulsants. Pregnant women under anticonvulsant therapy should receive 
prophylactic vitamin K1 therapy for one month prior to, and during, delivery. 
The total daily dosage should not exceed 2 g. Since PRIMIDONE therapy generally 
extends over prolonged periods, a complete blood count and a sequential multiple 
analysis-12 (SMA-12) test should be made every six months. 
 
In Nursing Mothers 
There is evidence that in mothers treated with PRIMIDONE, the drug appears in the 
milk in substantial quantities. Since tests for the presence of PRIMIDONE in biological 
fluids are too complex to be carried out in the average clinical laboratory, it is suggested 
that the presence of undue somnolence and drowsiness in nursing newborns of 
PRIMIDONE treated mothers be taken as an indication that nursing should be 
discontinued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Literature review 
1) Borst SI, et al.,(1975)[10]Comparative plasma level studies on different 
brands of sodium diphenylhydantoin (DPH) and primidone are described. 
Steady state plasma levels of both drugs were measured in epileptic patients 
who were chronically maintained on this medication. Simultaneous 
measurements of phenobarbital, primidone and diphenylhydantoin were 
carried out by gas chromatography. Drug product equivalence and clinical 
significance of plasma levels of DPH and primidone are discussed. 
 
2) Meyer MC at al., (1993) [11] Problems related to bioequivalence and 
bioavailability for four antiepileptic drugs (AEDs) are reviewed. 
Bioequivalence and bioavailability of AEDs can be affected by many factors, 
including physicochemical characteristics of the agent, the dosage form, and 
physiological condition of the patient. In 1988, breakthrough seizures 
prompted an FDA investigation of one company's generic carbamazepine 
tablets. Results indicated that the manufacturer had changed its source of 
carbamazepine, which led to a wide range of dissolution characteristics for 
different lots of tablets. In two separate studies, clonazepam was shown to be 
more rapidly absorbed in patients with a normal gastric pH than in those with 
a higher-than-normal gastric pH. With phenytoin, which exhibits nonlinear 
pharmacokinetics, differences in the rate and extent of absorption can 
adversely affect the bioavailability of this agent. Finally, the bioequivalence of 
generic primidone was contested in an adolescent girl who appeared to 
experience more frequent seizures with a generic product than with a trade 
formulation. The effectiveness of a drug depends on complex interactions 
involving the drug, the drug product formulation, and the patient. Minimizing 
variability in the absorption process is particularly important with AEDs, 
because of their narrow therapeutic range. 
3) Agarwal S et al., (12)A randomized, two-way crossover study was conducted 
in 24 fasting healthy male volunteers of Indian origin to compare the 
bioavailability of two brands of a fixed dose combination of escitalopram 
oxalate (CAS 219861-08-2) 10 mg and clonazepam (CAS 1622-61-3) 0.5 mg 
tablets, using Estomine-zee as test and a commercially available formulation 
as the reference product. The pharmacokinetics of escitalopram oxalate and 
clonazepam individually after oral administration of tablet formulation has 
been extensively evaluated in adult volunteers. However, no published data 
are available regarding the pharmacokinetics and bioavailability of this 
particular fixed dose combination. METHOD: The trial was designed as a 
randomized, balanced, open-label, 2-period cross-over study. The drug was 
administered with 240 ml of water after a 10-h overnight fasting on two 
treatment days separated by a 21-day washout period. After dosing, serial 
blood samples were collected for a period of 96 h. Plasma harvested from 
blood was analyzed by simple rapid, selective and validated liquid 
chromatography-electrospray mass spectrometry (LC-ESI-MS/ MS) using 
diazepam (CAS 439-14-5) as an internal standard. RESULTS: The calibration 
curves were found to be linear in the range of 1-25 ng/ml and 1-10 ng/ml for 
escitalopram oxalate and clonazepam, respectively, with a mean correlation 
coefficient of more than 0.99. No statistically significant differences were 
obtained between the two products with respect to the mean concentration-
time profiles or in the pharmacokinetic parameters, including the area under 
the serum concentration-time curve from the present study. CONCLUSION: 
Based on the statistical inferences, it was concluded that the test product is 
bioequivalent to the reference product. Both preparations were well tolerated 
with no adverse reactions throughout the study. 
 
4) Kongpatanakul S, et al.,(13)Oseltamivir, an ester prodrug of its active 
carboxylate metabolite, is an effective neuraminidase inhibitor used to treat 
influenza A and B virus infections. The purpose of this study was to compare 
the bioavailability of two 75 mg oral formulations of oseltamivir: a generic 
drug, GOP-A-Flu (test, Government Pharmaceutical Organization, Thailand) 
and Tamiflu (reference, Hoffmann-La Roche Ltd., Nutley, NJ, USA) in 
healthy volunteers. SUBJECTS AND METHODS: A single-dose, 
randomized, 2-sequence, crossover study was conducted in 24 healthy Thai 
volunteers. Each volunteer received a 75 mg capsule of the reference or test 
drugs under fasting conditions. Blood samples were collected before dosing 
and at various time points up to 48 hours after dosing and analyzed for plasma 
oseltamivir and oseltamivir carboxylate concentrations. The pharmacokinetic 
parameters including Cmax, AUC0-t, AUC0-infinity, tmax and t1/2 were 
analyzed using the non-compartmental method. Drug safety was assessed. 
RESULTS: 23 volunteers completed both treatment periods. The geometric 
mean ratios (test/reference) between the two formulations of oseltamivir were 
96.83% (90% CI, 76.85 - 123.15%) for Cmax 103.66% (86.44 - 113.56%) for 
AUC0-t, and 103.98% (86.44 - 113.56%) for AUC0-infinity. Those of 
oseltamivir carboxylate were 102.17% (90% CI, 90.90 - 109.10%) for Cmax, 
103.95% (90.90 - 109.10%) for AUC0-t, and 103.95% (90.92 - 109.08%) for 
AUC0-infinity. No significant difference of the tmax of oseltamivir and 
oseltamivir carboxylate between the two formulations was detected (p > 0.05). 
Both formulations were well-tolerated. CONCLUSION: Although the Cmax 
of oseltamivir was the only parameter not entirely within the equivalence 
criteria, the two capsule formulations were considered bioequivalent in terms 
of rate and extent of absorption regarding its active carboxylate metabolite. 
 
5) Henney HR 3rd et al., (14) BACKGROUND: The alpha2-adrenergic agonist 
tizanidine has been reported to have a narrow therapeutic index. A 
multiparticulate capsule formulation of tizanidine has been developed in an 
attempt to improve patient tolerability. OBJECTIVE: This study assessed 
bioequivalence between a single, intact, 6-mg capsule of tizanidine and the 
capsule contents sprinkled in applesauce in fasted healthy subjects. 
METHODS: Healthy male and female subjects aged 18 to 45 years completed 
2 treatment periods: one with a tizanidine 6-mg capsule administered intact 
and the other with capsule contents sprinkled in applesauce. The 2 treatment 
periods had a 6-day washout period between administrations. Plasma 
tizanidine concentrations were determined for blood samples collected over 
24 hours after administration. All treatment-emergent adverse events were 
recorded and graded by intensity and relationship to the study drug (not, 
improbable, possible, probable, definite) by the attending physician based on 
his or her clinical impression. RESULTS: A total of 19 men and 9 women 
(mean age, 26 years) completed the trial. Geometric mean natural logarithm-
transformed AUC values (AUC(0-infinity) [AUC to infinity] and AUC(0-t) 
[AUC to the last measurable time point]) and C(max) ratios were significantly 
(P <or= 0.035) increased to 1.14 (90% CI, 105.47%-127.01%), 1.16 (90% CI, 
106.80%-130.53%), and 1.17 (90% CI, 103.95%-133.66%), respectively, 
when the contents were sprinkled, with 90% CIs laying outside the 0.80 to 
1.25 ratio established by regulatory authorities for bioequivalence. A total of 
31 adverse events were reported by 17 of the 28 subjects (61%), including 15 
subjects (54%) with the intact capsule reporting 18 events and 11 subjects 
(39%) with the sprinkled contents reporting 13 events. No serious adverse 
events or deaths were reported, and no subjects were discontinued due to 
adverse events. CONCLUSIONS: The contents of the tizanidine capsule 
sprinkled in applesauce were not bioequivalent to the intact 6-mg capsule in 
these fasted healthy volunteers. Therefore, if switching from the intact capsule 
to the capsule contents mixed in applesauce, monitoring for adverse events is 
recommended; in this situation, dose adjustment could be necessary. 
 
6.0 DESIGN AND CONDUCT OF STUDY15 
 
A bioequivalence study is basically a comparative bioavailability study designed 
to establish equivalence between test and reference products. The design should be based 
on a reasonable knowledge of the pharmacokinetics of the active substance in question. 
The design and conduct of the study should follow ICH/ EU-regulations on Good 
Clinical Practice, including reference to an Ethics Committee. The rights, safety, and well 
being of all trial subjects must always be respected and should be given special attention. 
 
DESIGN OF BA/BE FACILITIES 
A general BE study facility includes various departments like the Clinical 
department, Bioanalytical department, Bio-statistics and Data management division and a 
Quality assurance (QA) department. Each department in turn consists of different 
functional areas.  
 
The Clinical facility has many subdivisions  
• Clinical Pharmacological Units (CPU) with areas for Phlebotomy, Dosing 
stations, recreation and refreshment rooms with safety precautions taken. 
• Separate areas for, sample separation, deep freezers. 
• Full time medical vigilance and care. 
• ICU and emergency medical care services. 
• Diagnostic lab services. 
• Biowaste disposal services. 
 
The Bioanalytical facility comprises of various functional areas like: 
• Analytical lab. 
• Sample processing room. 
• Washing room. 
• Store room for chemicals and solvents. 
• Mass balance room. 
The pharmacokinetics and statistics division is associated with functions like: 
• Pharmacy. 
• Sample size calculations. 
• Statistical analysis. 
• Study design. 
• Data collection, verification and analysis. 
• Report preparation as per the regulatory standards. 
 
Quality Assurance department generally functions as an independent unit for indirect 
enforcement of stringent quality standards to the whole study process and system. It is 
responsible for planning and conducting regular audits in all the departments to ensure 
that all the activities are carried out in accordance to the approved protocol, and in 
accordance with the laboratory standards. It independently verifies all the raw data 
generated during the study process for its completeness, accuracy and authenticity. 
 
6.1 STUDY DESIGN 
 
The study should be designed in such a way that the formulation effect can be 
distinguished from other effects. If the number of formulations to be compared is two, a 
two-period, two-sequence crossover design is often considered to be the design of choice. 
However, under certain circumstances and provided the study design and the statistical 
analyses are scientifically sound alternative well-established designs could be considered 
such as parallel design for very long half-life substances and replicate designs for 
substances with highly variable disposition  
 
In the present study the design followed was open-label, balanced, randomized, two-
treatment, two-period, two-sequence, single dose, crossover bioequivalence study. 
 
It is an open labeled study as the subjects and the investigator were not is blinded towards 
the identity of the study medications.  
6.2 WASHOUT PERIOD:  
 
Subsequent treatments should be separated by periods long enough to eliminate the 
previous dose before the next one (adequate wash out periods). In steady-state studies 
wash out of the previous treatment last dose can overlap with the build-up of the second 
treatment, provided the build-up period is sufficiently long (at least three times the 
terminal half-life). 
In the present study drug administration in first period was followed by a washout period 
of 14 days before subjects were switched over to the other treatment in the second period. 
6.3 SELECTION OF SUBJECTS: 
The subject population for bioequivalence studies should be selected with the aim to 
minimize variability and permit detection of differences between pharmaceutical 
products. Therefore, the studies should normally be performed with healthy volunteers. 
The inclusion/exclusion criteria should be clearly stated in the protocol. Subjects could 
belong to either sex; however, the risk to women of childbearing potential should be 
considered on an individual basis. 
In general, subjects should be between 18 - 50 years old capable of giving informed 
consent and of weight within the normal range according to accepted normal values for 
the Body Mass Index (BMI) of 18-25. The BMI is calculated using the formula: 
 
2min Height 
Kgsin Weight BMI =  
The number of subjects required is determined by 
• The error variance associated with the primary characteristic to be studied as 
estimated from a pilot experiment, from previous studies or from published data, 
• The significance level desired, 
• The expected deviation from the reference product compatible with 
bioequivalence (delta, i.e. percentage difference from 100 %) and the required 
power. 
 
The number of subjects required is calculated by the formula: 
 
N= (tα, 2N-2+tβ, 2N-2)2 [CV/ (V-δ)] 2 
 
Where N=number of subjects 
T=appropriate value from the t-distribution 
α=type 1 error 
β=type 2 error 
δ=Treatment difference 
CV=coefficient of variance (intra subject) 
V=Bioequivalence limit 
Calculations are quite tedious and time consuming, thus it is done using statistical 
software and statistical tools. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table – II  SUBJECT DEMOGRAPHICS16 
Smoking habit Food habit S. No Sub No 
Yes No Veg Non-Veg 
Age 
(years) 
Height 
(cms) 
Weight 
(kgs) 
Remarks 
01 01 -- √ -- √ 22 162 53 -- 
 
02 02 -- √ -- √ 28 168 70 -- 
 
03 03 √ -- -- √ 20 166 64 1cigarette/day 
 
04 04 -- √ -- √ 21 157 50 -- 
 
05 05 -- √ -- √ 22 160 57 -- 
 
06 06 √ -- -- √ 28 169 74  
1cigarette/day 
07 07 -- √ -- √ 22 166 54  
-- 
08 08 -- √ -- √ 20 165 53  
-- 
09 09 -- √ -- √ 21 166 53  
-- 
10 10 -- √ -- √ 22 168 56  
-- 
11 11 √ -- -- √ 20 165 62  
2cigarettes/day 
12 12 -- √ -- √ 25 161 50  
-- 
13 13 -- √ -- √ 23 174 61  
-- 
14 14 -- √ -- √ 24 168 63  
-- 
AVERAGE 22.7 165.3 58.5  
                       
STANDBY 
 
Depending on the nature of adverse effects associated with the drug, there might be 
chances of subjects being dropped out from the study. In such cases, results obtained 
from the study might not be significant and unaccepted by him regulatory. To prevent 
such situation few subjects are included in the study as standby. The dropout subject data 
is replaced by another subject’s data that was given the same sequence of treatment as the 
dropout during the study. Usually, 10% of the sample size is considered as standby. 
Standby is decided on the basis of literature available about the drug and the pilot study. 
An even number of subjects on the higher side is taken as the number of subjects to be 
included in standby. 
 
 
¾ In the present study, 14 subjects were included out of which 2 of them were 
standby. So the number of subjects participating in the study was represented as 
12+2 standby. 
 
6.4 PHARMACOKINETIC SAMPLING: 
 
Under normal circumstances, blood, rather than urine or tissue, should be used. In most 
cases, drug, or metabolites are measured in serum or plasma. However, in certain cases 
whole blood may be more appropriate for analysis.  
 
 
Blood samples should be drawn at appropriate times to describe the absorption, 
distribution, and elimination phases of the drug. The sampling schedule should be 
planned to provide an adequate estimation of Cmax and to cover the plasma concentration 
time curve long enough to provide a reliable estimate of the extent of absorption. This is 
generally achieved if the AUC derived from measurements is at least 80% of the AUC 
extrapolated to infinity. For most drugs, 12 to 18 samples, including a predose sample, 
should be collected per subject per dose. This sampling should continue for at least three 
or more terminal half lives of the drug. The exact timing for sample collection depends 
on the nature of the drug and the input from the administered dosage form. The sample 
collection should be spaced in such a way that the maximum concentration of the drug in 
the blood (Cmax) and terminal elimination rate constant (λz) can be estimated accurately. 
 
 
 For drugs with a long half-life, relative bioavailability can be adequately estimated using 
condensed AUC as long as the total collection period is justified.  
According to the Cmax and Tmax values of drug PRIMIDONE, the sampling schedule and 
amount of blood to be collected will be decided.  
 
 
In each period, a total of 23 venous blood samples were collected from each subject as 
per the following schedule: 
 
 
 
Predose (00 hr), 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 5.00, 
6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post dose in each 
period. 
The total volume of blood collected from each subject during the study did not exceed 
241 ml. which included: 
Table - III 
Screening 10 ml 
Study analysis 10 ml at the time of predose in each period. 
In-house 203 ml(23*2*4ml+19ml discarded heparinized blood) 
Post study 8 ml 
Total 241 ml 
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  T                                                                                                            R 
 
 
N – Number of subjects, R – Reference Product, T – Test Product 
 
 
 
6.5 PARAMETERS TO BE INVESTIGATED 
 
In most cases evaluation of bioavailability and bioequivalence will be based upon the 
measured concentrations of the parent compound. In some situations, however, 
measurements of an active or inactive metabolite may be necessary instead of the parent 
Randomization 
Period I 
 
 
Treatment R (6 + 1) Treatment T (6 + 1) 
Washout 
(At least 7 Days)
Period II 
 
 
 
Treatment T (6 + 1) Treatment R (6 + 1) 
 
Crossover 
compound. The use of a metabolite may be advantageous to determine the extent of drug 
input, e.g. if the concentration of the active substance is too low to be accurately 
measured in the biological matrix (major difficulty in analytical method, product unstable 
in the biological matrix or half-life of the parent compound too short) thus giving rise to 
significant variability. 
In bioavailability studies, the shape of the area under the plasma concentration versus 
time curves is mostly used to assess extent and rate of absorption. From the primary 
results, the bioavailability characteristics desired are estimated, namely AUC0-t,    
AUC0-∞, Cmax, Tmax, as appropriate, or any other justifiable characteristics. In 
bioequivalence studies the AUC0-t is the most reliable reflection of the extent of 
absorption. 
 
The following pharmacokinetic parameters are required for submission: 
• Plasma concentrations and time points.  
• Subject, period, sequence, treatment. 
• AUC0-t, AUC0-∞, Cmax, Tmax, λz, and t1/2.  
• Intersubject, intrasubject, and/or total variability, if available  
The following statistical information required for AUC0-t, AUC0-∞, and Cmax: 
• Geometric mean  
• Arithmetic mean  
• Ratio of means  
• Confidence intervals 
Rounding off of confidence interval values: 
Confidence interval (CI) values should not be rounded off; therefore, to pass a CI limit of 
80-125, the value should be at least 80.00 and not more than 125.00. 
 
7.0 CLINICAL PHASE17 
7.1 Communication from Sponsor 
 
Sponsor is an individual, company, institution or organization which takes responsibility 
for the initiation, management, and financing of a clinical study for the Drug product 
under investigation.  
The investigator of the study, after receiving information from the sponsor, starts 
preparing the protocol according to which the study is to be conducted.  
7.2 Preparation of Protocol                                     
Protocol is defined as a document signed and dated by the investigator and the sponsor 
that fully describes the objective(s), design, methodology, statistical considerations and 
organization of a study. The study protocol may also give the background and rationale 
for the study but these could be provided in other study protocol-referenced documents. 
The protocol includes all the details regarding the investigational product, the details 
regarding the administration of the drug, Pharmacokinetic (PK) sample withdrawal time-
points, safety assessment parameters etc. 
A protocol is prepared by the investigators of the study or his designee (usually a clinical 
pharmacologist and reviewed by various departments like analytical, statistical, QA to 
make necessary changes). The following chart gives an overview regarding the 
preparation of the protocol: 
 
 
 
 
 
 
 
 
 
 
EXTENSIVE LITERATURE SURVEY 
  
PREPARATION OF PROTOCOL 
  
REVIEW BY PRINCIPAL 
INVESTIGATOR/INVESTIGATORS 
  
CIRCULATION OF PROTOCOL TO 
DIFFERENT DEPARTMENTS FOR 
REVIEW 
  
INPUTS FROM VARIOUS 
DEPARTMENTS 
  
SENT TO THE QUALITY 
ASSURANCE (QA) DEPARTMENT 
FOR FINAL REVIEW. 
  
UNDERTAKE CHANGES GIVEN 
BY THE QA 
  
PROTOCOL SIGNED BY 
AUTHORIZED SIGNATORY 
  
APPROVAL FROM THE IEC 
7.3 ETHICAL CONSIDERATIONS  
 
Basic Principles 
 
The study was conducted according to Good Clinical Practice, the Declaration of 
Helsinki, Guideline for Good Clinical Practice and all Applicable regulations and 
guidance. 
 
Institutional Review Board 
 
An institutional review board / independent Ethics committee reviewed this protocol and 
the study started only after the approval of the protocol by the institutional review board 
/ independent Ethics committee. 
 
 Independent Ethics Committee (IEC) consists of a board of members who look into             
the ethical issues of the study to be conducted.  The study operations can be initiated only 
after the protocol is approved by IEC.  
 
An IEC should safeguard the rights, safety, and well being of all trial subjects.                      
Special attention should be paid to trials that may include vulnerable subjects. The 
investigator may provide information on any aspect of the trial, but should not participate 
in the deliberations of the IEC or in the vote/opinion of the IEC. An IEC may invite 
nonmembers with expertise in special areas for assistance 
 
Composition, Functions, and Operations 
The IEC consists of a reasonable number of members, who collectively have the 
qualifications and experience to review and evaluate the science, medical aspects, and 
ethics of the proposed trial. It is recommended that the IEC should include  
(a) At least five members. 
(b) At least one member whose primary area of interest is in a nonscientific area. 
(c) At least one member who is independent of the institution/trial site. 
• Only those IEC members who are independent of the investigator and the sponsor 
of the trial should vote/provide opinion on a trial-related matter. 
• A list of IEC members and their qualifications should be maintained. 
• It should perform its functions according to written operating procedures, should 
maintain written records of its activities and minutes of its meetings, and should 
comply with GCP and with the applicable regulatory requirement(s). 
• Only members who participate in the IEC review and discussion should 
vote/provide their opinion and/or advice. 
 
 
Informed Consent  
 
Designated clinical research personnel informed the subjects before initiation of the study 
through an oral presentation regarding the purpose, procedures to be carried out, potential 
Hazards and rights of the subjects during the course of the study. 
 
Termination of the study 
 
     The Study Can be terminated at any point of time at the interest of subjects welfare 
7.4 Protocol Training 
After the approval of the protocol, it is discussed among the investigators of the study. 
The summary of the protocol that includes: 
• The name of the investigational product (drug to be administered to the subjects), 
Reference drug 
• Dose to be administered 
• Type of study whether it is a single center study, a fast or fed study, analyst study 
etc. 
• Number of subjects to be enrolled in the study 
• Kind of study etc, and other minute details like the Clinical Pharmacology unit 
(CPU) in which the subjects would be housed etc,  
 
This summarized version of the protocol is discussed among the personnel in the facility 
to train them in the protocol.  
7.5 Registration of Volunteers 
For recruiting volunteers for a study suitable volunteers are selected from the database. 
New people are informed and registered in the database after they gave the written 
consent. Generally, healthy male, adult volunteers in the age group of 18-45 years are 
preferred according LIC height and weight chart.   
• Screening 
The screening will be carried out after taking an initial informed consent from 
volunteers for study screening procedures and will include the following: 
1. Demographic data, including sex, height and weight, BMI, nutrition status, diet, 
history of smoking, substances of abuse (Benzodiazepines, opoids and 
Amphetamine), alcohol, blood donation and previous participation in drug research 
study. 
2. Medical and treatment history including present complaints (if any), relevant past 
medical history, family history, history of any allergy to food or drug, medication 
history in the last six months. 
3. Complete physical examination including recording of vital signs (B.P, Pulse, 
Temperature and respiratory rate) and systemic examination. 
4. 12-lead ECG. 
5. Chest X-ray (PA view) 
6. Urine test to determine the consumption of drugs like morphine, codeine, LSD or 
any other drug of abuse (on the day of check in). 
7. Blood and urine samples will not be sent for laboratory examination if the subject 
fails in eligibility assessment during medical examination. 
8. Breathe alcohol test (on the day of check in). 
 
 
 
 
• Laboratory Parameter Investigations 
Table - IV 
Pre–study laboratory evaluation parameters 
CLINICAL CHEMISTRY HEMATOLOGY SEROLOGY 
Random blood sugar Total W.B.C HIV-1 
 Blood urea nitrogen(BUN) Total R.B.C HIV-2 
creatinine Hemoglobin HbsAg 
Total bilirubin PCV HCV 
SGOT Neutrophils  
SGPT lymphocytes  
blood cholesterol Mixed cells  
Total proteins platelets  
Sodium  ESR(1hr)  
potassium   
 
 
•       Withdrawal Criteria 
Subjects may be withdrawn from the study by the principal investigator or co-
investigators for any of the following reasons during the course of the study: 
1. If the subject suffers from significant illness 
2. If the subject requires concomitant medications which may interfere with 
pharmacokinetic of the study drug 
3. If the subject has entered the study in violation of the inclusion and the exclusion 
criteria 
4. If the subject is found to be non co-operative 
5. If the subject decides to voluntarily dropout from the study 
• Note: 
Any such subject withdrawals will be reported for reasons for withdrawal (if any) 
Medical examination of the subject will be done at the time of withdrawal / dropout,   
The plasma concentration data from subjects who are withdrawn due to adverse events 
will be presented, but will not be included in the statistical analysis. 
 7.6 Subject Details  
Total 14 healthy, adult, human, male volunteers were enrolled after drug of abuse 
screening and breath analysis for alcohol and all of them were admitted.  
 
Gross Demographics Data  
Average age of subjects in the study                                                      : 22.7 years   
Average weight of subjects in the study                                                 : 58.5 kgs 
Average height of subjects in the study                                                  : 165.3 cms 
Informed Consent Form (ICF) 
 ICF is designed as per the ICH-GCP and local regulatory requirements. ICF is conducted 
in order to get the consent from the volunteer to participate in the study. Volunteers were 
given all the information regarding the study including: 
 Details of Investigational products 
 Adverse events that may occur during the study 
 The total blood loss 
 The compensation to be given at the end of the study 
 Regulations to be followed while participating in the study 
 
Volunteers were given the freedom to withdraw from the study at any point of time, 
during the study. This consent is taken as a part of the ethical issue in conducting a 
BA/BE study. Every care was taken to protect the health of the volunteers. The 
volunteers signed on this form and gave their consent for participating in the study. Once 
they were enrolled in to the study, they were called ‘subjects’. The enrollment in the 
study started with the “check-in” process. 
7.7Check-in Process 
The volunteers who gave their consent to participate in the study were enrolled in the 
study i.e. the check-in process. During this process it is checked whether the person has 
met all the inclusion/exclusion criteria and cleared the screening process.  
 
 • Inclusion Criteria 
1. Subjects who will provide written consent form. 
2. Healthy males within the age range of 18 to 45 years 
3. Preferably Non- Smokers 
4. Willingness to provide written informed consent to participate in the study 
5. Body mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/ m2, with body weight not less than 
50 kg 
6. Absence of significant disease or clinically significant abnormal laboratory values 
or laboratory evaluation, medical history or physical examination during the 
screening 
7. Have a normal 12-lead ECG or one with abnormality considered to be clinically 
insignificant 
8. Have a normal chest X-ray. 
9. Comprehension of the nature and purpose of the study and compliance with the 
requirement of the distributed ICF. 
 
• Exclusion Criteria 
1. Personal/Family history of allergy or hypersensitivity to  the  drug or allied drugs 
2. Any major illness in the past 90 days or any clinically significant ongoing chronic 
medical illness e.g. Congestive Cardiac Failure (Heart failure), Hepatitis, 
Hypotensive episodes, Hyperglycemia etc 
3. Presence of any clinically significant abnormal values during screening e.g. 
significant abnormality of liver function test, renal (kidney) function test etc 
4. Severe cardiac, renal or liver impairment, gastro-intestinal disease or other 
conditions, any other organ or system impairment 
5. History of seizures, epilepsy or any kind of Neurological disorders 
6. Past history of Anaphylaxis or angioedema 
7. Presence of disease markers of HIV – 1 and 2 and hepatitis B, C virus 
8. Consumed alcohol within 48 hrs prior to dosing 
9. Consumption of Xanthine containing derivatives (coffee, tea, cola – drinks, 
chocolate) or tobacco products within 48 hours prior to dosing 
10. Use of any recreational drug or a history of drug addiction 
11. Participation in any clinical trial within the past 90 days 
12. History of difficulty with donating blood or difficulty in accessibility of veins in left 
or right arm 
13. Donation of blood (one unit or 350 ml) within 90 days prior to receiving the first 
dose of study medication 
14. Receipt of any other prescription drug or over the counter (OTC) drugs within two 
weeks prior to receiving the first dose of study medication or repeated use of drugs 
within the last four weeks 
15. An unusual diet for whatever reason e.g. low sodium diet, for two weeks prior to 
receiving any medication and throughout subject’s participation in the study 
16. Recent history of dehydration from diarrhea, vomiting or any other reason within a 
period of 24 hours prior to the study 
They will undergo vital examination and Medical examination again to ensure they are fit 
for participation in the study. They would be changing into the uniforms provided to 
them in the facility. Once the check-in of the volunteer is completed he would be called 
as ‘subject’. The subjects are provided with all the requirements they need including 
recreational activities like movies and games, newspapers. The check in day is called as 
Day 0.The subjects are given standardized dinner after which they will be fasting 
overnight for 10 hours. 
 
 
 
 
 
 
 
 
 
7.8 Randomization  
The test and reference products were assigned to each subject in a sequence according 
to a predetermined randomization schedule prepared by using SAS software 9.1 
version. The randomization schedule prepared is as follows: 
 
Table - V 
 
SUBJECT  
I.D 
Sequence Period - I Period - II 
001 1 T R 
002 2 R T 
003 1 T R 
004 2 R T 
005 2 R T 
006 1 T R 
007 1 T R 
008 2 R T 
009 1 T R 
010 2 R T 
011 2 R T 
012 1 T R 
013 1 T R 
014 2 R T 
 
 
 
7.9 Dispensing 
 
As per the randomization schedule a qualified registered pharmacist dispensed the 
investigational products under the supervision of Quality Assurance personnel in both the 
periods. Remaining drug products were stored in their original container as retention 
samples. The test and reference product were stored in humidity chamber below 25°C 
and 60% RH ± 5%. 
The dispensed tablets were transferred to the drug-dispensing containers as unit 
doses. The drug-dispensing containers used for dispensing were properly labeled for the 
study number, period number, subject number, treatment code, initial and date of the 
person dispensing the product. 
 
The details of the investigational project were as follows: 
Table - VI 
 
Test product T: Reference product R:  
PRIMIDONE tablets 50 mg PRIMIDONE tablets 50 mg 
 
Batch no: PDN-T050-F028 
 
Batch no: E0500110 
 
Description: White to off white, 
round, Flat, beveled edge, uncoated 
tablets, Embossed with RDY477on 
one side and break line on other 
side. 
Description: White, square shaped, 
Flat, uncoated tablets embossed with 
50 and break line on one side and “M” 
on other side of tablet. 
Assay: Containing not less than 
95.0% and not more than 105.0% 
of Test drug. 
Assay: Containing not less than 
99.40% and not more than 105.0%of 
Reference drug. 
 
 
7.10 Dosing of Investigational product 
  
The subjects were dosed next morning with the investigational product in the 
study after they have maintained 10hr fasting before dosing. The dosing day 
is called as Day 1. Dosing was done according to the procedure mentioned in 
the protocol and randomization code for the dosing is generated by the 
statistician, in which the sequence of investigational product administration 
was mentioned (eg. TR, RT). The investigational product was administered at 
0.00 hours in presence of clinical investigator. It was observed that the 
subjects were administered with the Investigational product with fixed 
amount of water (240ml) and swallows it completely. Compliance for dosing 
after drug administration was assessed by examination of the oral cavity of 
the subjects by trained study personnel immediately after dose 
administration in each period.  
Once the dosing was completed the blood samples from the subject were collected at time 
intervals mentioned in the protocol. One hour predose and 1 hours post dose water 
restriction was maintained. 
 
•      DISTRIBUTION OF MEAL 
 
  A standardized diet of approximately 2600 - 2800 calories per day was provided to the 
study subjects on the day of dosing.  
On the day prior to dosing dinner will be provided. All subjects were served with 
standardized lunch, snacks, dinner at 4, 9, and 13 post-dose respectively. 
7.11 Collection of blood samples 
 The subjects were cannulated on the day of dosing so that the blood withdrawal would 
be easier and to avoid the repeated needle pricks. Fixed volume of blood (generally 4 ml) 
was withdrawn at each time point. Samples were collected for all the subjects in each 
period pre-dose (00 hr), and 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 
4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours post dose. 
This was collected in the vacutainers containing the adequate amount of anticoagulant as 
(generally K3 EDTA); to avoid the mixing of the blood with the residual blood in the 
cannula 0.5ml blood is discarded before every sample collection. After the sample is 
collected 0.5ml saline will be pushed in the cannula to avoid the blockage of the cannula. 
The collected blood samples are sent to the separation room where the plasma is 
separated. After centrifugation at defined parameters in the protocol (generally 3800 rpm 
at 10 ± 2 °C for 10 minutes) and the plasma samples were stored at - 20°C ± 10°C. 
 
7.12 Safety monitoring 
Safety assessment was carried out at the time of screening and during the course of study 
by conducting medical examination, recording vital signs and adverse event monitoring.  
Medical examination (including vital signs) was carried out in each period, at 0.00, 2.00, 
4.00, 8.00, and 12.00 hours post dose.  
 
The normal vital signs range is as follows: 
Temperature  97.8 °F-99 °F 
Pulse Rate  60-100 beats/min 
Respiration Rate 14-20/min 
Systolic BP  100-138mm of Hg 
Diastolic BP  60-88mm of Hg 
If any adverse event is observed either by clinical staff or reported by subjects at times 
other than scheduled times will also be recorded. 
 
• Handling and Reporting of Adverse Events 
During the course of the study, subjects were monitored for adverse event, which was 
recorded in the appropriate raw data forms.  
The adverse events were recorded  
 
¾ At the time of check-in for subsequent period. 
¾ When reported by the subjects. 
¾ At the time of the vitals measurement and subject well being verification. 
¾ At the time of check out. 
A medical officer was available round the clock during the time of housing at the clinical 
facility of Bioserve clinical Research Private Limited. All drug and/or study related 
adverse events would be treated by the medical officer free of cost either at clinic or at a 
suitable nearby hospital.  Any adverse event discovered shall be appropriately treated and 
will be covered by an appropriate insurance policy. The ethics committee shall be 
informed immediately (within 24 hours) and regulatory bodies (whenever applicable) 
shall also be informed of the serious adverse event as mandated by the rules and 
regulations. 
Any serious adverse event will be reported to the Sponsor and Chairman of the Ethics 
Committee on identification either by telephone / fax within one working day of 
occurrence of event and full follow-up report to follow as soon as further information is 
available. Also, wherever applicable, regulatory authorities will be reported within 7 
working days. 
All adverse events shall be evaluated for duration, severity, action taken, date and time of 
resolution and causality with the study ‘treatment’. The study may be suspended or 
terminated depending on the seriousness of adverse event. 
Note: Adverse Drug Reactions (ADR) is all-noxious and unintended responses to a 
medicinal product related to any dose. 
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporarily associated with the use 
of a medicinal product, whether or not considered related to the medicinal product. This 
can include any unfavorable and unintended signs (such as rash or enlarged liver), or 
symptoms (such as nausea or chest pain), an abnormal laboratory finding (including 
blood tests) or a disease temporarily associated with the use of the study medication. 
A Serious Adverse Event (SAE) or reaction is any untoward medical occurrence that at 
any doses results in: 
– Death 
– Is life- threatening 
 Note: The term ‘life- threatening’ in the definition of ‘serious’ refers to an event 
in which the patient was at risk of death at the time of the event; it does not refer to an 
event, which hypothetically might have caused death if it were more severe. 
– Requires inpatient hospitalization or prolongation of existing   
hospitalization  
– Results in persistent or significant disability / incapacity, or  
– Results in a congenital anomaly / birth defect. 
 
The expected adverse events in the study were ataxia, vertigo, nausea, anorexia, 
vomiting, fatigue, hyperirritability, emotional disturbances, diplopia, nystagmus, and 
drowsiness. 
 
 
 
The adverse events occurred in the study were as follows: 
Table - VII 
 
Subject Number Period  Adverse Events Action Taken 
S1 I Drowsiness 
S7 I Vertigo 
S10 I Headache 
S11 I Vertigo 
S12 I Vertigo 
S1, 3, 5, 8, 11,13 II Drowsiness 
Recovered without 
Medication 
 
7.13 Check out process 
 
After the completion of the study the subjects were checked- out. In the check out process 
the subjects undergo a medical check up to ensure that they are healthy even after 
participating in the study.  
The study cycle was repeated after the washout period when the subjects are crossed over 
to other treatment.  
Their post study medical check up includes the blood test. Once the subjects finish giving 
their blood samples they are paid their compensation. 
 
 
 
 
 
  
 
 
 
 
7.14 Subject Compensation 
The subjects will be compensated for the overall inconvenience borne during the study.  
In case of dropouts / withdrawal of a subject before completion of the study, the amount 
of proportionate compensation to the dropout / withdrawal subject will be as follows: 
 
Table - VIII 
 
Sr. 
No. 
Reasons of Withdrawal from the Study Compensation 
1. 
Principal Investigator / Medical Officer withdraw the 
subjects from the study based on medical decision. 
Full payment 
2. 
After the initiation of the study, subject withdraws on 
his own free will 
50% 
proportionate 
participation dues
3. 
The subject is withdrawn from the study on 
humanitarian grounds, with the permission of the 
Principal Investigator / Medical Officer. 
100% 
proportionate 
participation dues
4. 
Subject is dropped from the study due to violation of 
requirements of the study by the Principal Investigator / 
Medical Officer after signing the Informed Consent 
Form but before receiving any medications  
No payment 
5. 
Subject is withdrawn from the study by the Principal 
Investigator / Medical Officer because of willful 
misinformation on present and /or past medical 
No payment 
illness/history. 
 
 
7.15 Sample separation and Storage 
The collected blood samples received in vacutainers would be centrifuged at a particular 
RPM (3800 rpm) at a temperature of 10°C for around 10 minutes. The plasma gets 
separated due to the centrifugal force. This separated plasma is collected in two different 
tubes called aliquots. The aliquots are pre-labeled and sent to the deep freezer where the 
samples are stored at a temperature of –70 °C.  
Various precautions are taken while separating the plasma. The plasma is separated 
without touching the bed of blood cells.  Care should be taken that the samples are not 
exposed to room temperature for a long time. 
 
7.16 Sample Sorting 
Once all the samples from the subjects are collected, the samples are sorted. The sorting 
is done by separating the aliquots containing samples of different time points of each 
subject into easy sealing bags. Various conditions are maintained while sorting the 
samples, like the maintenance of low temperatures. Sorting is done in presence of dry ice 
to prevent the exposure of samples to room temperature and also to prevent their 
degradation due to thawing. 
These bags are sealed into various boxes and stored in the deep freezer, which are later 
handed over to the bio-analytical department with proper documentation for further 
processing 
 
7.17 Protocol Deviations  
        The details of protocol deviations occurred in the study are as follows: 
Table - IX 
 
Subject No Sample Time point  hr Reason for deviation 
S9 48.0 hr Absent 
S12 12, 72 hr Absent 
 
 
 
 
 
 
 
 
 
8.0 BIOANALYTICAL PHASE 
 
The bioanalytical part of bioequivalence trials should be conducted according to the 
applicable principles of Good Laboratory Practice (GLP). (EMEA / OECD GLP / WHO 
GLP STANDARD). The bioanalytical methods used to determine the active moiety 
and/or its biotransformation product(s) in plasma, serum, blood or urine or any other 
suitable matrix must be well characterized, fully validated and documented to yield 
reliable results that can be satisfactorily interpreted. 
8.1 Materials and Methods 
The list of materials and methods used during analytical phase of the study are discussed 
below: 
Method parameters 
Table - X 
 
Name Of the Drug Primidone 
Name Of the Analyte Primidone 
Molecular Wt. of Primidone 218.25 
Molecular Formula of Primidone C12H14N2O2 
Name Of the Internal Standard Oxcarbazepine 
Molecular Wt. of Oxcarbazepine 252.27 
Molecular Formula of Oxcarbazepine C15H12N2O2 
Calibration Range 20ng/mL to 2000 ng/ml 
Lower Limit of Quantification 20ng/mL 
Sample Processing Method Liquid Liquid Extraction 
Instrument Method  LC/MS/MS 
 
Chemicals and Reagents  
 
The following Chemicals were used in the estimation of Primidone 
 
Table - XI 
 
CHEMICAL GRADE 
Acetonitrile HPLC 
Methanol HPLC 
Ammonium Formate Fluka 
Formic Acid GR/AR 
Water Milli Q 
Tetra butyl methyl Ether GR/AR 
Sodium Hydroxide GR/AR 
 
 
8.2 Instrumentation 
Shimadzu HPLC equipped with pump, auto sampler, Mass spectrometer MDS SCIEX 
API 3200 LC/MS/MS and data acquisition system (Analyst Software Version 1.4.1) 
were used for the quantitative determination of analyte in human plasma. 
 
 
 
 
 
 
 
 
 
Chromatographic Conditions 
LC conditions 
Table - XII 
 
Parameter Conditions 
Flow Rate 0.6 ml/min (Isocratic) 
Injector Volume 40 µl 
Auto sampler Temperature  50 C 
Column Oven Temperature 400 C 
 
MS/MS Conditions 
Table - XIII 
 
Parameter Primidone Oxcarbazepine 
Declustering Potential 20 35 
Entrance Potential 10 10 
Collision Energy 35 40 
Collision Cell Entrance 
Potential 
20 25 
Collision Cell Exit 
Potential 
2 4 
Polarity Positive Positive 
 
 
8.3 Stock Solutions and sample Preparations 
 
Diluents:  Diluents were prepared by mixing Methanol and water in 1:1 ratio, mixed well 
and sonicated for 2 minutes. 
Stock Solution Analyte (Primidone):  10.09 mg of Primidone reference standard was 
weighed and transferred into 10 ml of volumetric flask and added with 3 ml of methanol, 
sonicated to dissolve and made up to the mark with the same solvent. 
Stock Solution Internal Standard (Oxcarbazepine):  10.05 mg of Oxcarbazepine 
reference standard is weighed and transferred into a 10 ml volumetric flask, 3ml of 
methanol is added and sonicated to dissolve and made up to the mark with the same 
solvent. 
           
8.4 Preparation of Quality Control Samples 
 
Quality control samples were Prepared using in selected human plasma as per the below 
model reference table. Quality control samples concentrations were calculated as per the 
actual concentration of the spiking solution, the spiking volume and the total volume 
were based on the requirement of the number of the quality control samples. 
Table - XIV 
 
Spiking Solutions 
CONC 
(µg/ml) 
Vol 
(µl) 
Diluen
t (ml) 
Total 
Vol 
(ml) 
Spiked 
solution 
Conc(ng/ml) 
ID Required 
Conc 
(ng/ml) 
Ratio 
75.0000 1.00 49.00 50.00 1500.0000 HQC 1500.0000 75% of 
highest 
50.2500 1.00 49.00 50.00 1005.0000 MQC 1000.0000 50% of 
highest 
2.7638 1.00 49.00 50.00 55.2760 LQC 55.0000 2.75 times of 
LLOQ 
1.1055 0.2 9.80 10.00 22.1100 LLOQ 
QC 
22.0000 110% of 
LLOQ 
 
 
 
 
 
Storage of Matrix Samples 
a) All matrix based samples were stored at -300 C or colder  
b) Dry extract was stored at -100 or colder 
c) Wet extracts were stored at 2 to 80 C  
8.5 Sample Processing & Extraction Technique (LLE) 
 
a) This is Applicable for the possessing of all matrix based samples  
b) 500 µl of plasma was taken in a test tube and 50 µl of internal standard solution 
(400 nano gram per ml), vortex for 10 to 15 sec in a shaker.  
c) 75 µl of 0.2 N NaOH is added to the test tube and vortex it for 15 to 20 seconds. 
d) Add 3 ml of tetrabutyl methyl ether into the above test tubes and put in shaker 
under vibration for 10 min. 
e) Centrifuge it for 5 minutes at 4000 rpm pipette out 2.7 ml of tetrabutyl methyl 
ether layer into another test tube and load into nitrogen evaporator 
f) Evaporate the tetra butyl methyl ether to dryness at a temperature of 400 C and at 
a pressure of 5 psi initially for about 5 minutes, followed by 25 psi about 15 
minutes 
g) Add 250 µl of reconstitution solution (Mobile Phase), vortex for about 30 sec, 
transfer to auto injector vial and proceed for analysis. 
8.6 Data Collection 
 
All data collection and integration (area mode) were performed by statistical analysis 
software systems. The intercepts and goodness of fit were determined by least squares 
linear regression analyses using the ratios of drug / internal standard peak areas of the CC 
standards. The concentrations of all the study samples, CC standards and QC samples 
were calculated by Analyst version 1.4.1 software systems. A weighting factor of 1/ 
(concentration)2 was used in the calculation of linear regression line with the following 
equation. 
                                       y = mx + b 
            Where, y = peak area ratio of analyte / internal standard  
  m = slope of the CC 
  x = concentration ratio of analyte / internal standard 
  b = y-axis intercept of the C 
 
 
 
Table - XV 
 
The plasma concentrations (ng) of the drugs obtained were as follows  
 
Subject-1 Subject-2 Subject-3 Subject-4 TIME 
POINTS Period-1 Period-2 Period-1 Period-2 Period-1 Period-2 Period-1 Period-2
0.00 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ 
0.33 795.5122 947.2327 BLQ 168.6635 714.3559 BLQ BLQ 30.3436 
0.67 805.5066 823.9751 30.3668 723.3303 780.0156 260.5474 32.3929 407.6498 
1.00 906.6731 922.9506 77.6182 804.4682 1083.7294 625.1278 70.6677 744.8823 
1.33 885.5609 822.4703 102.3430 875.5967 1003.2728 901.6177 270.3452 602.6882 
1.67 867.2002 910.5793 284.5106 886.0191 945.6885 1158.8768 654.6196 597.1412 
2.00 919.2609 961.5539 306.0968 1142.7619 1114.7129 1268.5597 718.9361 590.6485 
2.33 887.5220 838.3983 382..4266 875.9405 1068.7753 1161.0420 767.5626 799.6163 
2.67 830.5983 938.2990 701.1376 864.9664 926.2478 1035.1097 736.001 603.7996 
3.00 903.0058 847.0168 786.7926 1016.6159 1004.2299 1086.2361 757.4860 741.4913 
3.33 800.9101 822.8384 870.8831 857.4108 941.5748 1003.2783 1197.8513 707.5560 
3.67 828.3049 761.3667 847.2607 878.3686 953.2477 944.2588 800.6677 710.1647 
4.00 855.5040 892.3737 1141.6796 896.0254 914.2805 1093.3308 572.1982 851.7415 
5.00 787.6936 699.2319 867.7271 870.2898 887.0890 930.1700 666.8247 740.8939 
6.00 770.330 794.6099 799.1474 853.6756 834.7647 948.7364 728.9634 824.2058 
8.00 741.1016 710.4758 893.0873 829.5155 983.3764 748.6339 594.6363 675.5202 
10.00 590.0876 639.2422 804.0446 647.3423 1131.7944 692.2361 586.9043 567.0021 
12.00 598.7577 579.3651 756.6855 720.6503 661.9151 640.8641 610.9892 579.4316 
16.00 485.4336 463.8485 674.6471 610.5195 557.1924 562.3615 433.0035 440.0556 
24.00 408.3297 413.1775 595.8033 589.5981 454.6277 447.8442 314.3740 421.9569 
36.00 188.9068 268.9414 333.3757 375.8187 227.6630 304.4049 254.0826 258.3301 
48.00 158.2072 161.2934 190.3395 256.0387 156.8962 401.3480 186.1795 182.4546 
72.00 63.5760 75.2760 93.5644 142.9080 77.8760 72.6972 84.6704 101.3456 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject-5 Subject-6 Subject-7 Subject-8 TIME 
POINTS Period-1 Period-2 Period-1 Period-2 Period-1 Period-2 Period-1 Period-2
0.00 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ 
0.33 366.6232 685.7622 338.5693 52.8629 284.4067 100.4543 488.3520 82.9419 
0.67 578.2424 1185.8734 719.3155 722.8347 873.5804 710.8684 1086.5785 99.0105 
1.00 912.2314 844.5620 1145.1738 621.7813 978.6609 744.2809 831.7903 217.5547 
1.33 1024.3092 1072.4698 1067.8119 594.2504 713.1019 896.5370 710.8608 541.2518 
1.67 1042.7022 1288.7934 1038.5385 1077.3324 1016.6410 758.5018 678.1115 906.5869 
2.00 814.9772 1210.5706 1043.3136 1090.8598 954.3557 796. 2734 674.4253 709.9220 
2.33 1035.8535 1277.7111 1012.6626 1162.8566 971.9115 836.9546 777.4437 717.6326 
2.67 940.9772 1304.5853 1055.8744 1224.1304 966.5487 821.2462 642.3264 711.3024 
3.00 968.4381 1233.4049 935.8594 1079.2374 1018.5572 930.7450 587.7479 688.9124 
3.33 1240.5005 1244.5432 1022.3251 976.2727 935.7305 852.3651 688.0322 730.1991 
3.67 1173.9863 1094.9792 1089.8835 1183.8235 925.1486 953.5073 596.8700 716.5353 
4.00 1168.4691 1238.4336 1111.9109 1257.6883 702.9173 960.7402 643.3260 685.9113 
5.00 1035.7931 1109.2431 1038.7816 1160.0757 769.0731 855.6945 499.5161 692.3572 
6.00 1059.6896 1070.4614 952.3027 1097.8809 726.6649 845.8207 524.7505 742.2331 
8.00 1013.3562 980.1173 938.7786 1051.2966 705.3668 718.1814 538.2990 690.3396 
10.00 865.2928 910.8960 828.5804 1037.1813 634.0228 677.7919 542.4131 632.4632 
12.00 884.8547 805.3492 807.9791 918.3238 580.6137 649.0068 514.8594 550.0999 
16.00 609.2018 687.6082 584.1165 664.5009 452.5478 489.8529 460.7226 485.7548 
24.00 655.3250 536.2725 505.3746 583.9011 373.8493 364.7386 364.6750 381.8711 
36.00 430.3918 393.7316 457.9618 557.1123 232.5287 282.8742 264.5263 262.1476 
48.00 336.8821 266.4340 411.0409 381.0683 153.3229 200.3760 170.0679 200.2678 
72.00 174.5480 166.2749 246.2828 195.8913 59.1349 80.7777 78.5779 116.0798 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject-9 Subject-10 Subject-11 Subject-12 TIME 
POINTS 
(Hrs) 
Period-1 Period-2 Period-1 Period-2 Period-1 Period-2 Period-1 Period-2 
0.00 BLQ BLQ no peak BLQ BLQ BLQ BLQ BLQ 
0.33 625.4278 103.6269 33.6109 168.6958 BlQ 499.4407 889.8900 770.6729 
0.67 964.8641 1222.5468 248.2346 556.9724 BlQ 979.3912 858.7940 882.1268 
1.00 754.1471 1185.5342 489.0155 715.0209 BlQ 821.3291 684.8525 885.9771 
1.33 981.1961 1006.9688 780.0829 874.8497 28.6935 795.2971 1346.6967 843.1927 
1.67 997.4247 1274.2224 815.8738 853.8506 72.5851 756.3153 892.6437 727.0715 
2.00 831.1194 1193.7491 821.9824 847.1562 103.0993 684.1262 790.6754 706.6802 
2.33 967.9029 1167.7938 883.4192 850.3795 143.7443 987.9591 987.7118 679.4585 
2.67 1034.1361 1205.0387 954.7133 833.0704 149.6566 896.2199 810.5118 642.2839 
3.00 817.7773 1201.4079 1037.5452 814.3912 551.1164 775.6969 1007.1974 874.3144 
3.33 939.6493 1110.4027 901.3122 868.1038 668.2478 918.0450 924.7291 732.3955 
3.67 860.6732 1053.3498 876.3602 859.0106 768.5237 827.6745 646.5832 849.9135 
4.00 994.5000 1027.4403 977.1979 901.7499 737.8230 754.9582 994.7462 759.3361 
5.00 891.1382 1003.6451 929.5762 793.6896 710.1949 667.0889 699.3830 688.0260 
6.00 718.3462 955.7431 746.5370 901.6039 775.8195 618.1807 738.9122 704.6378 
8.00 849.4305 1057.3754 769.1200 771.5552 715.5651 678.2709 873.8567 703.7738 
10.00 734.5604 864.2511 734.8537 841.2455 697.0790 487.2798 738.9122 711.0259 
12.00 745.2906 788.8073 663.5535 698.5064 628.0486 430.5915 760.5903 520.0823 
16.00 571.7317 676.4503 554.6093 532.6121 592.7050 340.0950 475.9240 451.5706 
24.00 490.6647 501.3881 486.1393 512.4101 421.0738 326.4136 478.2841 413.1769 
36.00 273.5781 285.6498 287.6714 287.5680 242.2215 203.5685 258.4034 243.0551 
48.00 absent 203.3989 232.2610 199.3008 184.1291 120.0949 259.6997 189.5752 
72.00 86.7601 79.6356 81.7516 90.4294 73.7823 70.3990 absent 100.3022 
 
 
 
 
 
 
 
 
 
 
 
 
9.0 Statistical methodology 
 
There is a growing need of the application of mathematical statistics to a wide range of 
biological processes. Most people working in scientific research are forced to apply some 
concepts of biostatistics into their work if they want to share their results with the 
scientific community. This community needs to be convinced in order to trust your 
approach. And this is mostly done by biostatistics in forms of significance tests, 
confidence intervals and so on. A researcher is forced to show that his experimental 
outcome is not just a matter of chance for convincing other researcher to apply his 
methodology. 
 
The following figure illustrates the statistical thinking process based on data in 
constructing statistical models for decision-making under uncertainties.  
 
 
 
Figure - IV 
 
The above figure depicts the fact that as the exactness of a statistical model increases, the 
level of improvements in decision-making increases. That's why we need statistical data 
analysis.  
 
The post study data obtained is analyzed using various statistical tools like the t-test, 
ANNOVA and the software like SAS and WinNonlin. 
 
Analysis Of Variance (ANOVA), a calculation procedure to allocate the amount of 
variation in a process and determine if it is significant or is caused by random noise. 
Using this statistical tool different parameters like the formulation effect, sequence affect, 
treatment effect between the test product and the reference product can be analysed.  
 
WinNonlin is the industry standard for pharmacokinetic, pharmacodynamic, and 
noncompartmental analysis. In addition to its extensive library of built-in PK, PD and 
PK/PD models, WinNonlin supports custom, user-defined models to address any kind of 
data. 
WinNonlin provides a complete solution with data management, statistical, modeling, 
and visualization tools in one package. Its worksheet interface facilitates data handling 
and transformations. Its descriptive statistics and linear mixed effects modeling engines 
provide flexible pre- and post-modeling analyses. The bioequivalence wizard supports 
FDA standards for average, individual and population bioequivalence assessment. 
Additional tools enable exploration of your drug’s properties through non-parametric 
superposition, semi compartmental modeling, deconvolution and nonparametric analysis 
of crossover studies. Finally, WinNonlin chart and table wizards, and automatic chart 
output from modeling, produce high-quality output for your study reports. 
 
Statistical analysis software (SAS) - includes a vast range of statistics for general 
statistical analysis which includes multiple linear regression, correlation, ANOVA 
(analysis of variance), chi-square, Fisher, McNemar, Wilcoxon, Mann-Whitney, 
Friedman, Kruskal Wallis, Shapiro-Wilk normality tests, histograms, summary statistics 
and many more. 
With the help of these software’s the PK parameters and statistical results are calculated 
for the data obtained after the completion of the study. 
 
 
 
RESULTS  
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9.1 Pharmacokinetic parameters  
Pharmacokinetic parameters and statistical analyses were calculated from subject 
concentrations using validated WinNonlin Version 5.1 and SAS Version 9.1 software 
procedures, respectively. 
Pharmacokinetic Data 
 
PK Parameter results based on untransformed data for drug in 12 subjects (Fasting) 
 
Table – XVI 
 
Treatment Subject Lambda_z HL_Lambda_z Tmax Cmax AUClast AUCINF Period Sequence 
R 1 0.0357 19.438 2 961.5539 24092.21 26203.18 2 TR 
R 2 0.0359 19.3024 4 1141.68 28513.34 31118.87 1 RT 
R 3 0.0345 20.106 2 1268.56 30638.97 32747.16 2 TR 
R 4 0.0309 22.4652 3.33 1197.851 21502.83 24247.03 1 RT 
R 5 0.0269 25.7391 3.33 1240.501 36715.47 43197.09 1 RT 
R 6 0.0288 24.0286 4 1257.688 39560.91 46351.68 2 TR 
R 7 0.0352 19.6647 4 960.7402 24861.6 27153.29 2 TR 
R 8 0.0335 20.6928 0.67 1086.579 21599.99 23945.81 1 RT 
R 9 0.0384 18.0636 1.67 1274.222 30357.22 32432.55 2 TR 
R 10 0.0339 20.4191 3 1037.545 27116.03 29524.3 1 RT 
R 11 0.0359 19.309 6 775.8195 22786.1 24841.45 1 RT 
R 12 0.0249 27.8786 1 885.9771 23880.31 27914.49 2 TR 
T 1 0.0385 18.0038 2 919.2609 22989.55 24640.87 1 TR 
T 2 0.0265 26.1638 2 1142.762 31320.06 36714.33 2 RT 
T 3 0.0297 23.3296 10 1131.794 26856.85 29477.96 1 TR 
T 4 0.0258 26.8887 4 851.7415 23406.31 27337.73 2 RT 
T 5 0.0264 26.2513 2.67 1304.585 34893.21 41190.48 2 RT 
T 6 0.0147 47.1075 1 1145.174 37065.03 53802.83 1 TR 
T 7 0.0382 18.1237 3 1018.557 22674.87 24221.07 1 TR 
T 8 0.0226 30.613 1.67 906.5869 23477.27 28603.96 2 RT 
T 9 0.0355 19.5458 2.67 1034.136 27760.83 30207.35 1 TR 
T 10 0.0322 21.4937 4 901.7499 27259.06 30063.17 2 RT 
T 11 0.0313 22.1221 2.33 987.9591 19457.3 21704.12 2 RT 
T 12 0.0307 22.6087 1.33 1346.697 23558.65 32029.41 1 TR 
 
 
 
 
 
9.2 Statistical Data 
The statistical results obtained for the drug during the fasting study were as follows: 
 
9.2.1 PK Parameter results based on untransformed data for drug in 12 subjects 
(fating) 
Table – XVII 
 
Treatment   Cmax Tmax AUC0-last AUC0-INF 
HL_Lamb
da_z Lambda_z 
Mean 1090.726 2.920 27635.414 30806.407 21.426 0.033 
SD 167.112 1.520 5831.224 7210.528 2.996 0.004 
CV% 15.321 52.030 21.101 23.406 13.983 12.505 
R 
Geometric 
Mean 1078.223 2.490 27117.472 30129.766 21.248 0.033 
Mean 1057.584 3.06 26726.5826 31666.1058 25.1876 0.0293 
SD 159.6985 2.38 5316.2684 8780.0679 7.8704 0.0068 
CV% 15.1003 77.81 19.8913 27.727 31.2471 23.0449 
T 
Geometric 
Mean 1046.904 2.54 26271.4831 30720.9243 24.3099 0.0285 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.2.2 Summarized statistical results of Primidone based on ln-transformed data in 
12 subjects (Fasting) 
Table – XVIII 
Parameter* Cmax  (ng /mL) AUC0-t  (ng hr/mL) AUC0-∞  (ng.hr/mL) 
 
Geometric 
LSM 
 
  T 
 
 
 
 
 
  R 
 
1046.9038 
 
1078.2232 
 
26271.4831 
27117.4723 
 
30720.9243 
30129.7662 
Geometric 
LSM 
Ratio 
 
T/ R 
 
97.10 
 
96.88 
 
101.96 
90% 
Confidence 
Interval: 
 T Vs. R 
Lower 
Limit 
Upper 
Limit 
 
86.86 % 
 
108.54 % 
 
93.09 % 
 
100.83 % 
 
95.58 % 
 
108.77 % 
p-values 
(ANOVA): 
 
Sequence 
Period 
Treatment 
0.4701 
0.6480 
0.6746 
0.6590 
0.7246 
0.7873 
0.6701 
0.8257 
0.8877 
Intra-subject 
Variability: 
15.14 5.40 8.75 
Power (%): 95.06 100 99.94 
 
The details of the ratios of means of test and reference parameters such as In-transformed 
Cmax, AUC0-t, AUC0-∞ of Test and Reference at 90% confidence interval were as follows: 
Table – XVIII 
 
Parameter Ratio (%) Lower limit Upper limit 
Cmax 97.10 86.86 108.54 
AUC0-t 96.88 93.09 100.83 
AUC0-∞ 101.96 95.58 108.77 
 
 
DISCUSSION 
The present thesis was subdivided in seven chapters, in these, 
In chapter 1- I had discussed about the bioserve clinical research company 
In chapter 2 - I had discussed about the introduction about bioavailability,      
                      bioequivalence,   and epilepsy etc. 
In chapter 3 - I had discussed about the main Objectives of the present study. 
In chapter 4 - I had discussed about drug profile of Primidone, its various  
                       pharmacokinetic and pharmacodynamic parameters  
 
In chapter 5 - I had discussed about Design and conduct of the study for the execution of  
                       the protocol and various parameters to be investigated  
In chapter 6 - I had discussed about the clinical phase of the study. This covers various  
                      aspects of patient related factors of the study. 
In chapter 7 - I had discussed about the Bioanalytical methods to characterize the  
                       presence of drug in the plasma.  
In chapter 8 - I had discussed about the various statistical methods and the results of the  
                       present study. 
 
Table no. 1 - Discusses Marketed Drugs Used to Treat Seizures 
Table no 2 -Discusses SUBJECT DEMOGRAPHICS 
Table no 3 - Discusses Total volume of blood collected from each subject during the  
                     Study. 
Table no 4 - Discusses Laboratory Parameter Investigations 
 Table no 5 - Discusses Randomization schedule 
 
Table no 6 - Discusses Details of Test and Reference drug 
 
 
Table no 7 - Discusses Adverse events occurred in the study for subjects 
 
Table no 8 - Discusses Subject Compensation 
 
Table no 9 - Discusses Protocol deviations occurred in the study 
 
Table no 10 - Discusses Materials and methods used during analytical phase of the study 
 
Table no 11 - Discusses Chemicals were used in the estimation of Primidone 
 
Table no 12 - Discusses Liquid Chromatographic conditions 
 
Table no 13 - Discusses MS/MS Conditions 
 
Table no 14 - Discusses Preparation of Quality Control Samples 
 
Table no 15 - Discusses plasma concentrations (ng) of the drugs 
 Table no 16 - Discusses PK Parameter results based on untransformed data for drug in 12                
                                  subjects (Fasting) 
 
Table no 17 -  Discusses statistical results obtained for the drug during the fasting study 
 
Table no 18 - Discusses Summarized statistical results of Primidone based on ln- 
                       transformed data in 12 subjects (Fasting) 
 
Table no 19 - Discusses Details of the ratios of means of test and reference parameters        
                       such as In-transformed Cmax, AUC0-t, AUC0-∞ of Test and Reference at  
                       90% confidence interval 
 
 
 
 
 
 
 
 
 
 
 
Glossary of terms  
 
1. Adverse Event: An adverse event is any untoward medical occurrence in clinical 
investigation subject administered a pharmaceutical product and that does not 
necessarily have a causal relationship with this treatment. 
 
2. Analysis of Variance (ANOVA): ANOVA is a statistical technique to identify 
sources of variance and estimate the degree of variability. In most bioavailability 
studies, there are three readily identified sources of variance namely formulation 
(Treatment), subject and period; hence it is a 3-way ANOVA.  
 
3. Area under the curve (AUC): Area under the curve is the total area under the 
biological fluid (serum, blood, etc.) concentration-time curve as determined by 
the Trapezoidal rule.  
 
4. AUC_Extrapolated (%): Calculated as {1 - (AUC0-t / AUC0-∞)} x 100. The 
mean AUC_Extrapolated (%) should be ≤ 20%. 
 
5. Bioavailability studies: It involves the determination of ‘Drug’ concentration in 
the blood or urine. Concern with how quickly and how much of a ‘Drug’ appears 
in the blood after a specific dose is administered. 
 
6. Cmax: This is the maximum ‘Drug’ concentration achieved in systemic circulation 
following ‘Drug’ administration 
 
7. Good Clinical Practice: A standard for the design, conduct, performance, 
monitoring, auditing, recording, analyses and reporting of clinical trials that 
provides assurance that the data and reported results are credible and accurate, 
and that the rights, integrity, and confidentiality of trial subjects are protected. 
 
8. Informed Consent: A process by which a subject voluntarily confirms his or her 
willingness to participate in a particular trial, after having been informed of all 
aspects of the trial are relevant to the subject’s decision to participate. Informed 
consent is documented by means of a written, signed, and dated informed consent 
form. 
 
9. Investigational Product: A pharmaceutical form of an active ingredient being 
tested or used as a reference in a clinical trial, including a product with a 
marketing authorization when used or assembled (formulated or packaged) in a 
way different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use. 
 
10. Kel: Apparent first-order terminal elimination rate constant calculated from a 
semi-log plot of the plasma concentration versus time curve, using the method of 
least square regression. 
 11. Protocol: A document that describes the objective(s), design, methodology, 
statistical consideration, and organization of a trial. The protocol usually also give 
the background and rationale for the trial, but these could be provided in other 
protocol referenced documents. Throughout the ICH-GCP Guidance, the term 
protocol refers to protocol and protocol amendments. 
 
12. Quality Assurance: All those planned and systematic action that are established to 
ensure that the trial is performed and the data are generated, documented 
(recorded), and reported in compliance with GCP and the applicable regulatory 
requirements(s). 
 
13. Quality Control: The operational techniques and activities undertaken within the 
quality assurance system to verify that the requirements for quality of the trial 
related activities have been fulfilled. 
 
14. Randomization: The process of assigning trial subject to treatment groups using 
an element of chance to determine the assignments in order to reduce bias. 
 
15. Sponsor-Investigator: An individual who both initiate and conducts, alone or with 
others, a clinical trial and under whose immediate direction the investigational 
product is administered to, dispensed to, or used by a subject. The term does not 
include any person other than an individual (e.g. it does not include a corporation 
or an agency). The obligations of a sponsor-investigator include both those 
sponsor and those of an investigator. 
 
16. Tmax: It is the time required to achieve maximum ‘Drug’ concentration in systemic 
circulation 
 
17. t1/2: Terminal half-life as determined by quotient 0.693/ Kel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
All the study procedures followed were in compliance with the protocol, the ICH-
GCP guidelines and Schedule Y.  
 
        From the analyses of pharmacokinetic and statistical results it was inferred 
that, for the ln-transformed data, the 90 % confidence interval about the test to reference 
ratio of Cmax, AUC0-t and AUC0-∞ of drug Primidone were falling within the 
bioequivalence acceptance range of 85.00 % - 109.00 %, which demonstrates the 
bioequivalence of test formulation ‘T’ with reference formulation ‘R’ under  fasting 
conditions. 
From the clinical data it can be concluded that the study objectives like the safety and 
efficacy of the test product has been achieved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX-I 
ACTIVITIES SCHEDULE 
Study phase 
 
Activity 
Screening 
With in 28 days 
of dosing 
Check-in day Dosing day 
Informed consent X X  
Medical history and 
demographic data 
X   
Physical examination X   
ECG (12-lead) X   
Vital signs measurement X   
Hematology X   
Urine analysis X   
Clinical chemistry X   
Serology(HIV-I&II, hepatitis 
B&C, RPR) 
X   
Urine drug screening ethanol, 
benzodiazepines, 
cannabionoids, amphetamines, 
cocaines, opiates (period-I) 
 X  
Record of concomitant 
medication 
 X X 
Check in procedures  X  
Alcohol screening(periods I&II) X X  
Confinement in study unit  X X 
Drug dosing   X 
PK blood sampling   X 
Adverse events monitoring  X X 
 
APPENDIX-II 
Pre-Study Laboratory Safety Evaluation Parameters 
Clinical chemistry 
S.No. PARAMETER REFERENCE 
INTERVALS 
UNITS 
1 Random blood glucose 70 to170 mg/dl 
2 Urea 15 to 40 mg/dl 
3 Creatinine 0.6 to 1.5 mg/dl 
4 Total bilirubin 0 to 1.0 mg/dl 
5 SGPT(ALT) 30 to 65 U/L 
6 SGOT(AST) 15 to 37 U/L 
7 Alkaline phosphatase(ALP) 50 to 136  U/L 
8 Albumin 3.7 to 5.3  g/dl 
9 Sodium 136 to149 mEq/L 
10 Potassium 3.8 to 5.2 mEq/L 
 
SEROLOGY 
SEROLOGY SCREENING INDICATION 
HIV-1&2 HIV ANTIBODIES AIDS 
Abs antigen& HCV HEPATITS B& HEPATITIS C VIRUS 
RPR Test SYPHILIS 
 
 
HAEMATOLOGY 
S.No. PARAMETER REFERENCE 
INTERVALS 
UNITS 
1 Total W.B.C 4000 to 1100 /cmm 
2 Total R.B.C 4.5 to 6.5 mil/cu mm 
3 Hemoglobin 14 to 18 gms% 
4 HCT(PCV) 40 to 54 Vol% 
5 Neutrophils 40 to 75 % 
6 Lymphocytes 20 to 40 % 
7 Eosinophils 01 to 06 % 
8 Monocytes 2 to 8 % 
9 Basophils 0 to1 % 
10 Platelets 104 to 400 x 103 /cmm 
11 ESR(1st hr) 0 to 15 mm 
URINE ANALYSIS 
PARAMETER 
Physical examination 
Color  
Transparancy 
Specific gravity 
pH 
Chemical examination 
Glucose  
Protein  
Ketones 
Blood 
Urobilinogen 
Bilirubin 
Microscopical examination 
Pus cells 
RBC’s 
Epithelial cells 
Crystals 
Casts 
others 
 
 
APPENDIX-III 
MEAL MENU FOR SUBJECTS PARTAKING 
 IN THE PRIMIDONE STUDY  
 
Pre-study dinner (Standard meal)Rice with one curry, dal, 
sambar, rasam, curd and papad 
Break fast  ------------------------ 
Lunch Standard meal 
Snacks Two somosa 
Dinner  Standard meal 
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